<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">PLoS One</journal-id>
<journal-id journal-id-type="iso-abbrev">PLoS ONE</journal-id>
<journal-id journal-id-type="publisher-id">plos</journal-id>
<journal-id journal-id-type="pmc">plosone</journal-id>
<journal-title-group>
<journal-title>PLoS ONE</journal-title>
</journal-title-group>
<issn pub-type="epub">1932-6203</issn>
<publisher>
<publisher-name>Public Library of Science</publisher-name>
<publisher-loc>San Francisco, CA USA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">32231385</article-id>
<article-id pub-id-type="pmc">7108727</article-id>
<article-id pub-id-type="doi">10.1371/journal.pone.0230977</article-id>
<article-id pub-id-type="publisher-id">PONE-D-19-34767</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Research Article</subject>
</subj-group>
<subj-group subj-group-type="Discipline-v3">
<subject>Biology and Life Sciences</subject>
<subj-group>
<subject>Biochemistry</subject>
<subj-group>
<subject>Metabolism</subject>
<subj-group>
<subject>Metabolic Pathways</subject>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
<subj-group subj-group-type="Discipline-v3">
<subject>Biology and Life Sciences</subject>
<subj-group>
<subject>Biochemistry</subject>
<subj-group>
<subject>Metabolism</subject>
<subj-group>
<subject>Amino Acid Metabolism</subject>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
<subj-group subj-group-type="Discipline-v3">
<subject>Biology and Life Sciences</subject>
<subj-group>
<subject>Biochemistry</subject>
<subj-group>
<subject>Lipids</subject>
<subj-group>
<subject>Sphingolipids</subject>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
<subj-group subj-group-type="Discipline-v3">
<subject>Biology and Life Sciences</subject>
<subj-group>
<subject>Biochemistry</subject>
<subj-group>
<subject>Metabolism</subject>
<subj-group>
<subject>Metabolites</subject>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
<subj-group subj-group-type="Discipline-v3">
<subject>Biology and Life Sciences</subject>
<subj-group>
<subject>Biochemistry</subject>
<subj-group>
<subject>Bioenergetics</subject>
<subj-group>
<subject>Energy-Producing Organelles</subject>
<subj-group>
<subject>Mitochondria</subject>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
<subj-group subj-group-type="Discipline-v3">
<subject>Biology and Life Sciences</subject>
<subj-group>
<subject>Cell Biology</subject>
<subj-group>
<subject>Cellular Structures and Organelles</subject>
<subj-group>
<subject>Energy-Producing Organelles</subject>
<subj-group>
<subject>Mitochondria</subject>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
<subj-group subj-group-type="Discipline-v3">
<subject>Medicine and Health Sciences</subject>
<subj-group>
<subject>Women's Health</subject>
<subj-group>
<subject>Maternal Health</subject>
<subj-group>
<subject>Pregnancy</subject>
<subj-group>
<subject>Pregnancy Complications</subject>
<subj-group>
<subject>Preeclampsia</subject>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
<subj-group subj-group-type="Discipline-v3">
<subject>Medicine and Health Sciences</subject>
<subj-group>
<subject>Women's Health</subject>
<subj-group>
<subject>Obstetrics and Gynecology</subject>
<subj-group>
<subject>Pregnancy</subject>
<subj-group>
<subject>Pregnancy Complications</subject>
<subj-group>
<subject>Preeclampsia</subject>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
<subj-group subj-group-type="Discipline-v3">
<subject>Physical Sciences</subject>
<subj-group>
<subject>Chemistry</subject>
<subj-group>
<subject>Chemical Compounds</subject>
<subj-group>
<subject>Organic Compounds</subject>
<subj-group>
<subject>Steroids</subject>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
<subj-group subj-group-type="Discipline-v3">
<subject>Physical Sciences</subject>
<subj-group>
<subject>Chemistry</subject>
<subj-group>
<subject>Organic Chemistry</subject>
<subj-group>
<subject>Organic Compounds</subject>
<subj-group>
<subject>Steroids</subject>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
<subj-group subj-group-type="Discipline-v3">
<subject>Biology and Life Sciences</subject>
<subj-group>
<subject>Biochemistry</subject>
<subj-group>
<subject>Metabolism</subject>
<subj-group>
<subject>Purine Metabolism</subject>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Effect of L-Ergothioneine on the metabolic plasma profile of the RUPP rat model of pre-eclampsia</article-title>
<alt-title alt-title-type="running-head">Metabolic profile of rat model of pre-eclampsia following L-Ergothioneine treatment</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-9692-9396</contrib-id>
<name>
<surname>Morillon</surname>
<given-names>Aude-Claire</given-names>
</name>
<role content-type="http://credit.casrai.org/">Data curation</role>
<role content-type="http://credit.casrai.org/">Formal analysis</role>
<role content-type="http://credit.casrai.org/">Investigation</role>
<role content-type="http://credit.casrai.org/">Methodology</role>
<role content-type="http://credit.casrai.org/">Writing – original draft</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff001">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff002">
<sup>2</sup>
</xref>
<xref ref-type="corresp" rid="cor001">*</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Williamson</surname>
<given-names>Rachel D.</given-names>
</name>
<role content-type="http://credit.casrai.org/">Resources</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff001">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Baker</surname>
<given-names>Philip N.</given-names>
</name>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff003">
<sup>3</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kell</surname>
<given-names>Douglas B.</given-names>
</name>
<role content-type="http://credit.casrai.org/">Conceptualization</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff004">
<sup>4</sup>
</xref>
<xref ref-type="aff" rid="aff005">
<sup>5</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kenny</surname>
<given-names>Louise C.</given-names>
</name>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff006">
<sup>6</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>English</surname>
<given-names>Jane A.</given-names>
</name>
<role content-type="http://credit.casrai.org/">Supervision</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff001">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff007">
<sup>7</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>McCarthy</surname>
<given-names>Fergus P.</given-names>
</name>
<role content-type="http://credit.casrai.org/">Supervision</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff001">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff002">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>McCarthy</surname>
<given-names>Cathal</given-names>
</name>
<role content-type="http://credit.casrai.org/">Conceptualization</role>
<role content-type="http://credit.casrai.org/">Funding acquisition</role>
<role content-type="http://credit.casrai.org/">Supervision</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff008">
<sup>8</sup>
</xref>
</contrib>
</contrib-group>
<aff id="aff001"><label>1</label>
<addr-line>INFANT Research Centre, Cork, Ireland</addr-line></aff>
<aff id="aff002"><label>2</label>
<addr-line>Department of Obstetrics and Gynecology, University College Cork, Cork, Ireland</addr-line></aff>
<aff id="aff003"><label>3</label>
<addr-line>College of Life Sciences, University of Leicester, Leicester, United Kingdom</addr-line></aff>
<aff id="aff004"><label>4</label>
<addr-line>Dept of Biochemistry, Institute of Integrative Biology, Faculty of Health and Life Sciences, University of Liverpool, Crown St, Liverpool, United Kingdom</addr-line></aff>
<aff id="aff005"><label>5</label>
<addr-line>Novo Nordisk Foundation Centre for Biosustainability, Technical University of Denmark, Lyngby, Denmark</addr-line></aff>
<aff id="aff006"><label>6</label>
<addr-line>Department of Women’s and Children’s Health, Institute of Translational Medicine, University of Liverpool, Liverpool, United Kingdom</addr-line></aff>
<aff id="aff007"><label>7</label>
<addr-line>Department of Anatomy and Neuroscience, University College Cork, Cork, Ireland</addr-line></aff>
<aff id="aff008"><label>8</label>
<addr-line>Department of Pharmacology and Therapeutics, University College Cork, Cork, Ireland</addr-line></aff>
<contrib-group>
<contrib contrib-type="editor">
<name>
<surname>Spradley</surname>
<given-names>Frank T.</given-names>
</name>
<role>Editor</role>
<xref ref-type="aff" rid="edit1"></xref>
</contrib>
</contrib-group>
<aff id="edit1">
<addr-line>University of Mississippi Medical Center, UNITED STATES</addr-line>
</aff>
<author-notes>
<fn fn-type="COI-statement" id="coi001">
<p><bold>Competing Interests: </bold>One of the authors, Douglas B Kell, is a named inventor on a European Patent application, as described in the open access article: van der Hoek SA, Darbani B, Zugaj K, Prabhala BK, Biron MB, Randelovic M, Medina JB, Kell DB, Borodina I: Engineering the yeast Saccharomyces cerevisiae for the production of L-(+)-ergothioneine. Front Bioeng Biotechnol 2019, 7:262. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. This does not alter our adherence to PLOS ONE policies on sharing of data/or materials.</p>
</fn>
<corresp id="cor001">* E-mail: <email>morillon.ac@gmail.com</email></corresp>
</author-notes>
<pub-date pub-type="epub">
<day>31</day>
<month>3</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="collection">
<year>2020</year>
</pub-date>
<volume>15</volume>
<issue>3</issue>
<elocation-id>e0230977</elocation-id>
<history>
<date date-type="received">
<day>16</day>
<month>12</month>
<year>2019</year>
</date>
<date date-type="accepted">
<day>12</day>
<month>3</month>
<year>2020</year>
</date>
</history>
<permissions>
<copyright-statement>© 2020 Morillon et al</copyright-statement>
<copyright-year>2020</copyright-year>
<copyright-holder>Morillon et al</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
</license>
</permissions>
<self-uri content-type="pdf" xlink:href="pone.0230977.pdf"></self-uri>
<abstract>
<sec id="sec001">
<title>Introduction</title>
<p>Pre-eclampsia is a major cause of maternal and fetal mortality and morbidity worldwide. Its pathophysiology remains unclear, but mitochondrial dysfunction and oxidative stress have been implicated. L-Ergothioneine is a naturally occurring, water-soluble betaine, that has demonstrated antioxidant properties. Using the reduced uterine perfusion pressure (RUPP) rat model of pre-eclampsia, this study aimed to define the plasma metabolic profile following treatment with L-Ergothioneine.</p>
</sec>
<sec id="sec002">
<title>Methods</title>
<p>The effect of L-Ergothioneine (ET) treatment was explored using <italic>in vivo</italic> treatment in rats: Sham control (SC, n = 5), RUPP control (RC, n = 5), Sham +ET (ST, n = 5), RUPP +ET (RT, n = 5). Differential expression of plasma metabolites were obtained using untargeted liquid chromatography coupled to mass spectrometry. Statistical analysis was performed on normalised data comparing RC to SC, RT to RC, and RT to ST. Metabolites significantly altered (FDR &lt; 0.05) were identified through database search.</p>
</sec>
<sec id="sec003">
<title>Results</title>
<p>We report significantly lower levels of L-palmitoylcarnitine in RC compared to SC, a fatty acyl substrate involved in beta-oxidation in the mitochondria. We report that a metabolite that has been associated with oxidative stress (Glutamylcysteine) was detected at significantly higher levels in RT vs RC and RT vs ST. Five metabolites associated with inflammation were significantly lower in RT vs RC and three metabolites in RT vs ST, demonstrating the anti-inflammatory effects of ET in the RUPP rat model of pre-eclampsia.</p>
</sec>
<sec id="sec004">
<title>Conclusions</title>
<p>L-Ergothioneine may help preserve mitochondrial function by increasing antioxidant levels, and reducing inflammatory responses associated with pre-eclampsia. This study shows the potential of L-Ergothioneine as a treatment for pre-eclampsia.</p>
</sec>
</abstract>
<funding-group>
<award-group id="award001">
<funding-source>
<institution-wrap>
<institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/501100001602</institution-id>
<institution>Science Foundation Ireland</institution>
</institution-wrap>
</funding-source>
<award-id>12/RC/2272</award-id>
<principal-award-recipient>
<contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-9692-9396</contrib-id>
<name>
<surname>Morillon</surname>
<given-names>Aude-Claire</given-names>
</name>
</principal-award-recipient>
</award-group>
<award-group id="award002">
<funding-source>
<institution-wrap>
<institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/100010414</institution-id>
<institution>Health Research Board</institution>
</institution-wrap>
</funding-source>
<award-id>HRB EIA-2017-023</award-id>
<principal-award-recipient>
<name>
<surname>English</surname>
<given-names>Jane A.</given-names>
</name>
</principal-award-recipient>
</award-group>
<award-group id="award003">
<funding-source>
<institution-wrap>
<institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/100010414</institution-id>
<institution>Health Research Board</institution>
</institution-wrap>
</funding-source>
<award-id>HRA-POR-2015-1240</award-id>
<principal-award-recipient>
<name>
<surname>Williamson</surname>
<given-names>Rachel D.</given-names>
</name>
</principal-award-recipient>
</award-group>
<award-group id="award004">
<funding-source>
<institution-wrap>
<institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/100010414</institution-id>
<institution>Health Research Board</institution>
</institution-wrap>
</funding-source>
<award-id>HRA-POR-2015-1240</award-id>
<principal-award-recipient>
<name>
<surname>McCarthy</surname>
<given-names>Cathal</given-names>
</name>
</principal-award-recipient>
</award-group>
<award-group id="award005">
<funding-source>
<institution-wrap>
<institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/501100009708</institution-id>
<institution>Novo Nordisk Fonden</institution>
</institution-wrap>
</funding-source>
<award-id>NNF10CC1016517</award-id>
<principal-award-recipient>
<name>
<surname>Kell</surname>
<given-names>Douglas B.</given-names>
</name>
</principal-award-recipient>
</award-group>
<funding-statement>ACM was funded by a Science Foundation Ireland (<ext-link ext-link-type="uri" xlink:href="https://www.sfi.ie/">https://www.sfi.ie/</ext-link>) (12/RC/2272), and CM and RDW are funded through Health Research Board Ireland (<ext-link ext-link-type="uri" xlink:href="https://www.hrb.ie/">https://www.hrb.ie/</ext-link>), (HRA-POR-2015-1240). JAE is funded by Health Research Board Ireland HRB EIA-2017-023. DBK thanks the BBSRC and the Novo Nordisk Foundation (<ext-link ext-link-type="uri" xlink:href="https://novonordiskfonden.dk/en/">https://novonordiskfonden.dk/en/</ext-link>) (grant NNF10CC1016517) for financial support. Waters Corporation provided access to mass spectrometry instrumentation (<ext-link ext-link-type="uri" xlink:href="https://www.waters.com/nextgen/us/en.html?locale=en_GB">https://www.waters.com/nextgen/us/en.html?locale=en_GB</ext-link>). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement>
</funding-group>
<counts>
<fig-count count="4"></fig-count>
<table-count count="2"></table-count>
<page-count count="21"></page-count>
</counts>
<custom-meta-group>
<custom-meta id="data-availability">
<meta-name>Data Availability</meta-name>
<meta-value>All relevant data are within the paper and its Supporting Information files.</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
<notes>
<title>Data Availability</title>
<p>All relevant data are within the paper and its Supporting Information files.</p>
</notes>
</front>
<body>
<sec id="sec005" sec-type="intro">
<title>Introduction</title>
<p>Pre-eclampsia (PE) is a hypertensive disorder of pregnancy, estimated to affect 3–5% of pregnancies worldwide annually, and leads to over 70,000 maternal deaths and 500,000 fetal and neonatal morbidities every year [<xref ref-type="bibr" rid="pone.0230977.ref001">1</xref>, <xref ref-type="bibr" rid="pone.0230977.ref002">2</xref>]. The International Society for the Study of Hypertension in Pregnancy (ISSHP) defines pre-eclampsia as <italic>de novo</italic> hypertension after 20 weeks of gestation with or without proteinuria, presence of signs of liver dysfunction, maternal acute kidney injury, hemolysis or thrombocytopenia, neurological features, with or without presence of fetal growth restriction [<xref ref-type="bibr" rid="pone.0230977.ref002">2</xref>]. Pre-eclampsia is associated with preterm birth, iatrogenic or spontaneous, and fetal growth restriction [<xref ref-type="bibr" rid="pone.0230977.ref001">1</xref>], outcomes which are associated with an increased risk of respiratory and neurological disorders in the fetus. The pathophysiology of pre-eclampsia is still not fully understood, but poor placentation leading to exaggerated oxidative stress and systemic inflammatory response have been implicated [<xref ref-type="bibr" rid="pone.0230977.ref003">3</xref>, <xref ref-type="bibr" rid="pone.0230977.ref004">4</xref>], as have dormant microorganisms [<xref ref-type="bibr" rid="pone.0230977.ref005">5</xref>, <xref ref-type="bibr" rid="pone.0230977.ref006">6</xref>]. Deficient placental implantation and failed trophoblastic invasion of the spiral arteries lead to impaired blood perfusion between the myometrium and placenta, in turn leading to placental oxidative stress and an excessive production of reactive oxygen species (ROS) [<xref ref-type="bibr" rid="pone.0230977.ref003">3</xref>, <xref ref-type="bibr" rid="pone.0230977.ref004">4</xref>, <xref ref-type="bibr" rid="pone.0230977.ref007">7</xref>, <xref ref-type="bibr" rid="pone.0230977.ref008">8</xref>]. ROS are reactive free radicals and other moieties which damage DNA, RNA and proteins; excessive production of ROS can overwhelm natural antioxidant defences and lead to oxidative stress [<xref ref-type="bibr" rid="pone.0230977.ref009">9</xref>]. Evidence of oxidative stress has been established in the well characterised reduced uterine perfusion pressure (RUPP) rat model of pre-eclampsia [<xref ref-type="bibr" rid="pone.0230977.ref010">10</xref>, <xref ref-type="bibr" rid="pone.0230977.ref011">11</xref>]. Mitochondria are the main cellular source of ROS, and mitochondrial oxidative stress has recently been implicated in the pathophysiology of PE [<xref ref-type="bibr" rid="pone.0230977.ref011">11</xref>–<xref ref-type="bibr" rid="pone.0230977.ref013">13</xref>]. In their study, Vaka <italic>et al</italic>. provided novel evidence that placental ischaemia disrupted mitochondrial function with increased generation of mitochondrial-specific ROS. Furthermore, they showed that the levels of mitochondrial ROS were elevated in endothelial cells incubated with serum from RUPP rats compared to control rats. In addition, this study showed that endothelial cells incubated with serum from RUPP rats treated with mitochondrial specific antioxidant lead to a decrease in the amout of mitochondrial ROS produced, compared to untreated rats [<xref ref-type="bibr" rid="pone.0230977.ref011">11</xref>]. These recent studies indicate that directly targeting mitochondrial dysfunction could be a potential therapeutic treatment for pre-eclampsia.</p>
<p>L-Ergothioneine (ET) is a naturally occurring, water-soluble amino acid and a derivative of histidine, first discovered in the ergot fungus [<xref ref-type="bibr" rid="pone.0230977.ref014">14</xref>, <xref ref-type="bibr" rid="pone.0230977.ref015">15</xref>]. Interestingly, the synthesis of ET has not been observed in animals or higher plants despite evidence of its accumulation in high concentration in animal and human tissues from dietary sources [<xref ref-type="bibr" rid="pone.0230977.ref016">16</xref>]; instead it exploits a solute carrier that has been seleced for this purpose [<xref ref-type="bibr" rid="pone.0230977.ref017">17</xref>]. Antioxidant properties of ET have been demonstrated by the reduction in markers of oxidative stress in blood samples taken from healthy human subjects, who were administered ET (5 or 25mg) once a day for 7 days [<xref ref-type="bibr" rid="pone.0230977.ref018">18</xref>]. The radical scavenging properties of ET are established, and this has led scientists to test it as a therapeutic agent in a range of pathologies, such as non-alcoholic fatty liver disease [<xref ref-type="bibr" rid="pone.0230977.ref019">19</xref>]. In addition, there is evidence that ET can accumulate in the mitochondrial fraction of hepatic cells in rats [<xref ref-type="bibr" rid="pone.0230977.ref020">20</xref>, <xref ref-type="bibr" rid="pone.0230977.ref021">21</xref>].</p>
<p>A recent study investigated ET as a therapeutic agent to alleviate clinical symptoms of pre-eclampsia using the well established reduced uterine perfusion pressure (RUPP) rat model of pre-eclampsia, and determined that its therapeutic properties may in part results from a reduction in mitochondrial-specific ROS [<xref ref-type="bibr" rid="pone.0230977.ref022">22</xref>]. Here, we aimed to explore the plasma metabolic profile of L-Ergothioneine treatment in the RUPP rat model of pre-eclampsia.</p>
</sec>
<sec id="sec006" sec-type="materials|methods">
<title>Materials and methods</title>
<sec id="sec007">
<title>Materials and reagents</title>
<p>L-Ergothioneine was provided by Tetrahedron (Paris, France; <ext-link ext-link-type="uri" xlink:href="http://www.tetrahedron.fr">www.tetrahedron.fr</ext-link>). Liquid chromatography grade methanol and formic acid were purchased from Fisher Scientific (Loughborough, UK). LC-MS glass vials and ultra-performance liquid chromatography (UPLC) column were purchased from Waters (Waters, Wexford, Ireland).</p>
</sec>
<sec id="sec008">
<title>Animals</title>
<p>University College Cork Biological Services Unit supplied and maintained the Sprague Dawley-timed pregnant rats used for the experiment. The animals had free access to food and tap water, and were maintained in a 12-hour light/dark cycle, at 21°C. All the procedures were performed in accordance with National Guidelines and the European Directive 2010/63/EU, under an authorization issued by the Health Products Regulatory Authority Ireland and approved by the Animal Ethics Committee of University College Cork (AE19130/P037).</p>
</sec>
<sec id="sec009">
<title>RUPP procedure</title>
<p>The RUPP procedure has been previously described [<xref ref-type="bibr" rid="pone.0230977.ref023">23</xref>, <xref ref-type="bibr" rid="pone.0230977.ref024">24</xref>], and is a well-established surgical method used to model the link between hypertension in the pregnant rat and placental ischemia. Briefly, on gestational day (GD) 14, silver clips (0.2mm ID) were placed on the abdominal aorta (one clip) above the iliac bifurcation under isoflurane anaesthesia; this procedure induced the reduction of blood flow to the uteroplacental unit. An additional two clips (0.1mm ID) were carefully positioned around the right and left ovarian arteries. As a control, Sham surgery was performed by creating an incision, without placing any clips on either ovarian arteries or abdominal aorta. A chronic indwelling catheter was inserted into the carotid artery on GD18, and mean arterial blood pressure (MABP) was recorded in conscious animals on GD19.</p>
</sec>
<sec id="sec010">
<title>L-Ergothioneine <italic>in vivo</italic> experimental protocol</title>
<p>The effect of the ET treatment was explored using four experimental groups (<xref ref-type="table" rid="pone.0230977.t001">Table 1</xref>): Sham control (SC, n = 5), RUPP control (RC, n = 5), Sham + ET (ST, n = 5), RUPP + ET (RT, n = 5). From GD11-GD19, ET was added to the drinking water at 25mg/kg/day, as reported in previous animal studies [<xref ref-type="bibr" rid="pone.0230977.ref025">25</xref>, <xref ref-type="bibr" rid="pone.0230977.ref026">26</xref>]. Blood was collected on GD19 into EDTA vacutainers, these were centrifuged at 2000<italic>g</italic> and 2400<italic>g</italic> for 10 minutes at 4°C, plasma was removed and stored at -80°C for further analysis.</p>
<table-wrap id="pone.0230977.t001" orientation="portrait" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0230977.t001</object-id>
<label>Table 1</label>
<caption>
<title>Description of animal procedures and L-Ergothioneine <italic>in vivo</italic> experiment.</title>
</caption>
<alternatives>
<graphic id="pone.0230977.t001g" xlink:href="pone.0230977.t001"></graphic>
<table frame="hsides" rules="groups">
<colgroup span="1">
<col align="left" span="1" valign="middle"/>
<col align="left" span="1" valign="middle"/>
<col align="left" span="1" valign="middle"/>
<col align="left" span="1" valign="middle"/>
<col align="left" span="1" valign="middle"/>
</colgroup>
<thead>
<tr>
<th align="center" colspan="1" rowspan="1"></th>
<th align="center" colspan="1" rowspan="1">Sham Control (n = 5)</th>
<th align="center" colspan="1" rowspan="1">RUPP Control (n = 5)</th>
<th align="center" colspan="1" rowspan="1">Sham + ET (n = 5)</th>
<th align="center" colspan="1" rowspan="1">RUPP + ET (n = 5)</th>
</tr>
</thead>
<tbody>
<tr>
<td align="center" colspan="1" rowspan="1">Gestational day 11–19</td>
<td align="center" colspan="1" rowspan="1">Drinking water</td>
<td align="center" colspan="1" rowspan="1">Drinking water</td>
<td align="center" colspan="1" rowspan="1">Drinking water + ET</td>
<td align="center" colspan="1" rowspan="1">Drinking water + ET</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1">Gestational day 14</td>
<td align="center" colspan="1" rowspan="1">Sham surgery</td>
<td align="center" colspan="1" rowspan="1">RUPP surgery</td>
<td align="center" colspan="1" rowspan="1">Sham surgery</td>
<td align="center" colspan="1" rowspan="1">RUPP surgery</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1">Gestational day 19</td>
<td align="center" colspan="4" rowspan="1">Caesarean Section, Blood and Tissue Collection Experiment Endpoint</td>
</tr>
</tbody>
</table>
</alternatives>
<table-wrap-foot>
<fn id="t001fn001">
<p>ET: L-Ergothioneine, administered in drinking water at 25 mg/kg/day.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="sec011">
<title>Plasma sample preparation</title>
<p>Plasma samples were prepared in a randomised order. Samples were taken from -80°C storage, and left on ice until thawed. Metabolite extraction was performed based on the protocol by Dunn <italic>et al</italic> [<xref ref-type="bibr" rid="pone.0230977.ref027">27</xref>], and as follows: cold methanol (300μl) was added to plasma (100μl), vortex mixed, and centrifuged at 15,800<italic>g</italic> for 15 minutes at room temperature. Supernatant (200μl) was transferred in two separate properly labelled Eppendorf tubes, and placed in a centrifugal vacuum evaporator for 4 to 5 hours, without applying any heating. Samples were then reconstituted in water (100μl), vortex mixed and centrifuged at 15,800<italic>g</italic> for 15 minutes at room temperature. Pooled quality control (QC) samples were obtained by taking 20μl from each samples. Finally, supernatant of all samples and QC were transferred into LC-MS glass vials.</p>
</sec>
<sec id="sec012">
<title>UPLC-MS analysis</title>
<p>Samples were maintained at 4°C during the analysis, analysed in randomised order and in triplicate, on an ultra-high performance liquid chromatography (UPLC) Acquity system coupled to a Synapt G2-S quadrupole time-of-flight (Q-TOF) mass spectrometry system (Waters Corp, Wilmslow, UK). Data were acquired in both positive and negative electrospray ionisation modes (ESI+, ESI-). QC samples were analysed after every 10 samples injections. The chromatographic separation of the analytes was performed on a BEH C18 column (2.1x100mm, 1.7μm) maintained at 50°C. For both ESI+ and ESI-, the elution gradient used solvent A, a mix of water and formic acid at 0.1% (v/v), and solvent B, a mix of methanol and formic acid at 0.1% (v/v). In ESI+, injection volume was 4μl, and a 22 minutes gradient was applied at 0.40ml/min, as follows: initial condition at 0% of B for 1 minute, increased to 100% of B over 15 minutes, then maintained for 4 minutes, followed by a return to initial conditions of 0% of B in 2 minutes. In ESI-, injection volume was 7μl, and a 24 minutes gradient was applied as follows: initial condition at 0% of B for 2 minutes, increased to 100% of B over 15 minutes, then maintained for 5 minutes, followed by a return to initial conditions of 0% of B in 2 minutes.</p>
<p>Data were acquired in “resolution” MS<sup>E</sup> mode [<xref ref-type="bibr" rid="pone.0230977.ref028">28</xref>, <xref ref-type="bibr" rid="pone.0230977.ref029">29</xref>], from 50 to 1,500Da. Ion data for precursor (low energy) and fragment (high energy) were collected during the same acquisition, with a total cycle time of 0.2 seconds (0.1 second for each). Linear collision energy ramp (20-40eV) was applied for high energy. Capillary voltage was set to 3.0kV, sampling cone at 40V, extraction cone to 5V. The source temperature was set at 120°C, and desolvation temperature at 650°C. Desolvation gas flow rate was set at 800L/h, and cone gas at 50L/h. Mass calibration was performed using a sodium formate mix (Waters, Wexford, Ireland), recommended by the manufacturer before each batch analysis. Real time lock mass correction was performed using leucine enkephalin (LeuEnk, 1ng/μl) mix, injected at 10μL/min through a lock-spray probe and acquired every 30 seconds.</p>
</sec>
<sec id="sec013">
<title>Data processing</title>
<p>Data processing was performed using Progenesis QI version 2.4 (Nonlinear dynamics, Newcastle, UK), an appropriate pooled QC was selected as the reference to chromatographically align the data, and normalise to all compounds. Data were then peak picked, and considered the adducts corresponding with M+H, M+H-2H<sub>2</sub>O, M+H- H<sub>2</sub>O, M+NH<sub>4</sub>, M+Na, M+K, 2M+H (ESI+), or M-H, M-H<sub>2</sub>O-H, M-Na-2H, M+K-2H, M+Cl, M+FA-H, 2M-H (ESI-). Downstream statistical analysis was performed using the compound measurements exported from Progenesis QI.</p>
</sec>
<sec id="sec014">
<title>Statistical analysis</title>
<p>Statistical analysis of the data was performed on data normalised to all compounds (using Progenesis QI), and on the averaged intensities of the replicate measures. Data from each group were compared using Student’s T test (unpaired, two-tailed, unequal variance) in order to determine which metabolites were significantly altered between the groups. In addition, false discovery rate (FDR) correction using Benjamini- Hochberg [<xref ref-type="bibr" rid="pone.0230977.ref030">30</xref>], and mean fold change were calculated. Analysis was performed with Excel 2016 Software, and significance was accepted for FDR &lt;0.05. Volcano plots and parallel coordinate plot were created using R statistical software [<xref ref-type="bibr" rid="pone.0230977.ref031">31</xref>] and the packages ggplot2 [<xref ref-type="bibr" rid="pone.0230977.ref032">32</xref>] and GGally [<xref ref-type="bibr" rid="pone.0230977.ref033">33</xref>].</p>
</sec>
<sec id="sec015">
<title>Putative annotation of metabolites</title>
<p>The exact mass of significant metabolites (FDR q-value &lt;0.05) were putatively annotated [<xref ref-type="bibr" rid="pone.0230977.ref034">34</xref>] by database search using the Progenesis QI identification tool against the Human Metabolome Database (HMDB, version 4) [<xref ref-type="bibr" rid="pone.0230977.ref035">35</xref>]. The search parameters were set for an exact mass tolerance 5ppm for the precursor ion, and 10ppm for the fragment ion. Metabolites detected using UPLC-MS are frequently present multiple times due to fragmentation, multiple charging, chemical adduction, or dimerization. Identifications were reported for unique metabolites, after removing duplicates and metabolites of drugs or food, and after checking the retention time. The metabolites reported were grouped into chemical classes using HMDB, and the biological pathways or functions that they are involved with are listed, using HMDB, the small molecule pathway database (SMPDB) [<xref ref-type="bibr" rid="pone.0230977.ref036">36</xref>], and Kyoto encyclopedia of genes and genomes (KEGG) [<xref ref-type="bibr" rid="pone.0230977.ref037">37</xref>] (<xref ref-type="table" rid="pone.0230977.t002">Table 2</xref>).</p>
<table-wrap id="pone.0230977.t002" orientation="portrait" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0230977.t002</object-id>
<label>Table 2</label>
<caption>
<title>Metabolites significantly altered (FDR q-value &lt;0.05) and putatively annotated, for RUPP +ET compared to Sham +ET, RUPP +ET compared to RUPP Control, and RUPP Control compared to Sham Control.</title>
</caption>
<alternatives>
<graphic id="pone.0230977.t002g" xlink:href="pone.0230977.t002"></graphic>
<table frame="hsides" rules="groups">
<colgroup span="1">
<col align="left" span="1" valign="middle"/>
<col align="left" span="1" valign="middle"/>
<col align="left" span="1" valign="middle"/>
<col align="left" span="1" valign="middle"/>
<col align="left" span="1" valign="middle"/>
<col align="left" span="1" valign="middle"/>
<col align="left" span="1" valign="middle"/>
<col align="left" span="1" valign="middle"/>
<col align="left" span="1" valign="middle"/>
<col align="left" span="1" valign="middle"/>
</colgroup>
<thead>
<tr>
<th align="left" colspan="1" rowspan="2">Annotated metabolites</th>
<th align="left" colspan="2" rowspan="1">RUPP +ET vs Sham +ET</th>
<th align="left" colspan="2" rowspan="1">RUPP +ET vs RUPP Control</th>
<th align="left" colspan="2" rowspan="1">RUPP Control vs Sham Control</th>
<th align="left" colspan="1" rowspan="2">Chemical class</th>
<th align="left" colspan="1" rowspan="2">Chemical sub-class</th>
<th align="left" colspan="1" rowspan="2">Biological function/pathway</th>
</tr>
<tr>
<th align="left" colspan="1" rowspan="1">FDR</th>
<th align="left" colspan="1" rowspan="1">FC</th>
<th align="left" colspan="1" rowspan="1">FDR</th>
<th align="left" colspan="1" rowspan="1">FC</th>
<th align="left" colspan="1" rowspan="1">FDR</th>
<th align="left" colspan="1" rowspan="1">FC</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1">9'-Carboxy-alpha-chromanol</td>
<td align="left" colspan="1" rowspan="1">1.29E-02</td>
<td align="char" char="." colspan="1" rowspan="1">5.95</td>
<td align="left" colspan="1" rowspan="1">3.41E-02</td>
<td align="char" char="." colspan="1" rowspan="1">2.37</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Benzopyrans</td>
<td align="left" colspan="1" rowspan="1">1-benzopyrans</td>
<td align="left" colspan="1" rowspan="1">vitamin E biosynthesis</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Glutamylcysteine OR Cysteinyl-Glutamate</td>
<td align="left" colspan="1" rowspan="1">1.37E-02</td>
<td align="char" char="." colspan="1" rowspan="1">2.18</td>
<td align="left" colspan="1" rowspan="1">8.46E-03</td>
<td align="char" char="." colspan="1" rowspan="1">11.11</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Carboxylic acids and derivatives</td>
<td align="left" colspan="1" rowspan="1">Amino acids, peptides, and analogues</td>
<td align="left" colspan="1" rowspan="1">Glutathione metabolism</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Glycyl-Serine OR Serylglycine</td>
<td align="left" colspan="1" rowspan="1">1.53E-02</td>
<td align="char" char="." colspan="1" rowspan="1">2.02</td>
<td align="left" colspan="1" rowspan="1">3.14E-02</td>
<td align="char" char="." colspan="1" rowspan="1">3.57</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Carboxylic acids and derivatives</td>
<td align="left" colspan="1" rowspan="1">Amino acids, peptides, and analogues</td>
<td align="left" colspan="1" rowspan="1">Protein catabolism</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Asparaginyl-Lysine OR Lysyl-Asparagine</td>
<td align="left" colspan="1" rowspan="1">1.69E-02</td>
<td align="char" char="." colspan="1" rowspan="1">-1.28</td>
<td align="left" colspan="1" rowspan="1">4.32E-02</td>
<td align="char" char="." colspan="1" rowspan="1">-1.21</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Carboxylic acids and derivatives</td>
<td align="left" colspan="1" rowspan="1">Amino acids, peptides, and analogues</td>
<td align="left" colspan="1" rowspan="1">Protein catabolism</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">L-Phenylalanine</td>
<td align="left" colspan="1" rowspan="1">2.25E-02</td>
<td align="char" char="." colspan="1" rowspan="1">6.02</td>
<td align="left" colspan="1" rowspan="1">1.95E-02</td>
<td align="char" char="." colspan="1" rowspan="1">8.19</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Carboxylic acids and derivatives</td>
<td align="left" colspan="1" rowspan="1">Amino acids, peptides, and analogues</td>
<td align="left" colspan="1" rowspan="1">Phenylalanine and Tyrosine Metabolism</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">L-Glutamic acid</td>
<td align="left" colspan="1" rowspan="1">4.72E-02</td>
<td align="char" char="." colspan="1" rowspan="1">1.91</td>
<td align="left" colspan="1" rowspan="1">4.30E-02</td>
<td align="char" char="." colspan="1" rowspan="1">2.64</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Carboxylic acids and derivatives</td>
<td align="left" colspan="1" rowspan="1">Amino acids, peptides, and analogues</td>
<td align="left" colspan="1" rowspan="1">Alanine, Histidine, Cysteine Metabolism, Malate-Aspartate Shuttle, Ammonia Recycling</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Histidinyl-Methionine OR Methionyl-Histidine</td>
<td align="left" colspan="1" rowspan="1">4.81E-02</td>
<td align="char" char="." colspan="1" rowspan="1">2.27</td>
<td align="left" colspan="1" rowspan="1">4.10E-02</td>
<td align="char" char="." colspan="1" rowspan="1">4.71</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Carboxylic acids and derivatives</td>
<td align="left" colspan="1" rowspan="1">Amino acids, peptides, and analogues</td>
<td align="left" colspan="1" rowspan="1">Protein catabolism</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Asymmetric OR symmetric dimethylarginine</td>
<td align="left" colspan="1" rowspan="1">2.29E-02</td>
<td align="char" char="." colspan="1" rowspan="1">2.01</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Carboxylic acids and derivatives</td>
<td align="left" colspan="1" rowspan="1">Amino acids, peptides, and analogues</td>
<td align="left" colspan="1" rowspan="1">Protein catabolism</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Nonenoylglycine</td>
<td align="left" colspan="1" rowspan="1">3.36E-04</td>
<td align="char" char="." colspan="1" rowspan="1">5.99</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Carboxylic acids and derivatives</td>
<td align="left" colspan="1" rowspan="1">Amino acids, peptides, and analogues</td>
<td align="left" colspan="1" rowspan="1">Protein catabolism</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Hydroxyprolyl-Isoleucine OR Hydroxyprolyl-Leucine</td>
<td align="left" colspan="1" rowspan="1">3.12E-03</td>
<td align="char" char="." colspan="1" rowspan="1">2.11</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Carboxylic acids and derivatives</td>
<td align="left" colspan="1" rowspan="1">Amino acids, peptides, and analogues</td>
<td align="left" colspan="1" rowspan="1">Protein catabolism</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Alanyltryptophan OR Tryptophyl-Alanine</td>
<td align="left" colspan="1" rowspan="1">1.33E-02</td>
<td align="char" char="." colspan="1" rowspan="1">-3.66</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Carboxylic acids and derivatives</td>
<td align="left" colspan="1" rowspan="1">Amino acids, peptides, and analogues</td>
<td align="left" colspan="1" rowspan="1">Protein catabolism</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">N,O-Bis- (trimethylsilyl)phenylalanine</td>
<td align="left" colspan="1" rowspan="1">4.88E-02</td>
<td align="char" char="." colspan="1" rowspan="1">3.45</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Carboxylic acids and derivatives</td>
<td align="left" colspan="1" rowspan="1">Amino acids, peptides, and analogues</td>
<td align="left" colspan="1" rowspan="1">Protein catabolism</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Pyridinoline</td>
<td align="left" colspan="1" rowspan="1">4.68E-02</td>
<td align="char" char="." colspan="1" rowspan="1">2.04</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Carboxylic acids and derivatives</td>
<td align="left" colspan="1" rowspan="1">Amino acids, peptides, and analogues</td>
<td align="left" colspan="1" rowspan="1">Protein catabolism</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Histidinyl-Isoleucine OR Histidinyl-Leucine OR Isoleucyl-Histidine OR Leucyl-Histidine</td>
<td align="left" colspan="1" rowspan="1">2.51E-02</td>
<td align="char" char="." colspan="1" rowspan="1">-1.39</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Carboxylic acids and derivatives</td>
<td align="left" colspan="1" rowspan="1">Amino acids, peptides, and analogues</td>
<td align="left" colspan="1" rowspan="1">Protein catabolism</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">N-Heptanoylglycine OR 3-Hydroxyisoheptanoic acid OR Ethyl 2-hydroxyisovalerate</td>
<td align="left" colspan="1" rowspan="1">4.54E-02</td>
<td align="char" char="." colspan="1" rowspan="1">4.92</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Carboxylic acids and derivatives</td>
<td align="left" colspan="1" rowspan="1">Amino acids, peptides, and analogues</td>
<td align="left" colspan="1" rowspan="1">Protein catabolism</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Histidinylhydroxyproline</td>
<td align="left" colspan="1" rowspan="1">4.87E-02</td>
<td align="char" char="." colspan="1" rowspan="1">-1.19</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Carboxylic acids and derivatives</td>
<td align="left" colspan="1" rowspan="1">Amino acids, peptides, and analogues</td>
<td align="left" colspan="1" rowspan="1">Protein catabolism</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">20-COOH-leukotriene E4</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">2.49E-02</td>
<td align="char" char="." colspan="1" rowspan="1">1.56</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Carboxylic acids and derivatives</td>
<td align="left" colspan="1" rowspan="1">Amino acids, peptides, and analogues</td>
<td align="left" colspan="1" rowspan="1">Arachidonic acid metabolism</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Histidinyl-Tyrosine OR Asparaginyl-Tryptophan OR Tyrosyl-Histidine OR Tryptophyl-Asparagine</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">2.86E-02</td>
<td align="char" char="." colspan="1" rowspan="1">-2.64</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Carboxylic acids and derivatives</td>
<td align="left" colspan="1" rowspan="1">Amino acids, peptides, and analogues</td>
<td align="left" colspan="1" rowspan="1">Protein catabolism</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Diphthamide</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">2.80E-02</td>
<td align="char" char="." colspan="1" rowspan="1">-2.08</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Carboxylic acids and derivatives</td>
<td align="left" colspan="1" rowspan="1">Amino acids, peptides, and analogues</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Asparaginyl-Methionine OR Methionyl-Asparagine</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">4.91E-02</td>
<td align="char" char="." colspan="1" rowspan="1">12.39</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Carboxylic acids and derivatives</td>
<td align="left" colspan="1" rowspan="1">Amino acids, peptides, and analogues</td>
<td align="left" colspan="1" rowspan="1">Protein catabolism</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Cysteinyl-Glutamate OR Glutamylcysteine</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">3.73E-02</td>
<td align="char" char="." colspan="1" rowspan="1">8.94</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Carboxylic acids and derivatives</td>
<td align="left" colspan="1" rowspan="1">Amino acids, peptides, and analogues</td>
<td align="left" colspan="1" rowspan="1">Protein catabolism</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Neuromedin N (1–4)</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">4.24E-03</td>
<td align="char" char="." colspan="1" rowspan="1">-4.56</td>
<td align="left" colspan="1" rowspan="1">Carboxylic acids and derivatives</td>
<td align="left" colspan="1" rowspan="1">Amino acids, peptides, and analogues</td>
<td align="left" colspan="1" rowspan="1">Neuropepetide</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Tyrosyl-Phenylalanine OR Phenylalanyl-Tyrosine</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">4.64E-02</td>
<td align="char" char="." colspan="1" rowspan="1">-1.96</td>
<td align="left" colspan="1" rowspan="1">Carboxylic acids and derivatives</td>
<td align="left" colspan="1" rowspan="1">Amino acids, peptides, and analogues</td>
<td align="left" colspan="1" rowspan="1">Protein catabolism</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">L-Acetylcarnitine</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">8.22E-03</td>
<td align="char" char="." colspan="1" rowspan="1">-1.53</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Fatty Acyls</td>
<td align="left" colspan="1" rowspan="1">Fatty acid esters</td>
<td align="left" colspan="1" rowspan="1">Beta Oxidation of Very Long Chain Fatty Acids, Oxidation of Branched Chain Fatty Acids</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">L-Palmitoylcarnitine</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">2.06E-02</td>
<td align="char" char="." colspan="1" rowspan="1">-10.35</td>
<td align="left" colspan="1" rowspan="1">Fatty Acyls</td>
<td align="left" colspan="1" rowspan="1">Fatty acid esters</td>
<td align="left" colspan="1" rowspan="1">Fatty acid Metabolism, Fatty acid Degradation</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">trans-Hexadec-2-enoyl carnitine OR Galactosylsphingosine OR Glucosylsphingosine</td>
<td align="left" colspan="1" rowspan="1">4.62E-02</td>
<td align="char" char="." colspan="1" rowspan="1">3.32</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Fatty Acyls</td>
<td align="left" colspan="1" rowspan="1">Fatty acid esters</td>
<td align="left" colspan="1" rowspan="1">Sphingolipid metabolism</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Azelaic acid</td>
<td align="left" colspan="1" rowspan="1">1.69E-02</td>
<td align="char" char="." colspan="1" rowspan="1">-2.29</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Fatty Acyls</td>
<td align="left" colspan="1" rowspan="1">Fatty acids and conjugates</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">5-Methyltetrahydrofolic acid (folic acid)</td>
<td align="left" colspan="1" rowspan="1">2.37E-02</td>
<td align="char" char="." colspan="1" rowspan="1">1.27</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Fatty Acyls</td>
<td align="left" colspan="1" rowspan="1">Fatty acids and conjugates</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">(S)-3-Hydroxytetradecanoyl-CoA</td>
<td align="left" colspan="1" rowspan="1">2.73E-02</td>
<td align="char" char="." colspan="1" rowspan="1">36.60</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Fatty Acyls</td>
<td align="left" colspan="1" rowspan="1">Fatty acyl thioesters</td>
<td align="left" colspan="1" rowspan="1">Fatty Acid Elongation In Mitochondria, Fatty acid metabolism, Mitochondrial Beta-Oxidation of Long Chain Saturated Fatty Acids</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">3-Oxotetradecanoyl-CoA</td>
<td align="left" colspan="1" rowspan="1">3.89E-02</td>
<td align="char" char="." colspan="1" rowspan="1">85.27</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Fatty Acyls</td>
<td align="left" colspan="1" rowspan="1">Fatty acyl thioesters</td>
<td align="left" colspan="1" rowspan="1">Fatty Acid Elongation In Mitochondria, Fatty acid metabolism, Mitochondrial Beta-Oxidation of Long Chain Saturated Fatty Acids</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">S-(2-Methylpropionyl)-dihydrolipoamide-E</td>
<td align="left" colspan="1" rowspan="1">2.96E-02</td>
<td align="char" char="." colspan="1" rowspan="1">3.66</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Fatty Acyls</td>
<td align="left" colspan="1" rowspan="1">Fatty amides</td>
<td align="left" colspan="1" rowspan="1">Valine, leucine and isoleucine degradation</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">13-Hydroxyoctadecadienoic acid (13-HODE) OR other fatty acyls—11 hits</td>
<td align="left" colspan="1" rowspan="1">3.93E-02</td>
<td align="char" char="." colspan="1" rowspan="1">2.86</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Fatty Acyls</td>
<td align="left" colspan="1" rowspan="1">Lineolic acids and derivatives</td>
<td align="left" colspan="1" rowspan="1">Linoleic acid metabolism</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">20-Oxo-leukotriene E4</td>
<td align="left" colspan="1" rowspan="1">2.35E-02</td>
<td align="char" char="." colspan="1" rowspan="1">2.88</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Fatty Acyls</td>
<td align="left" colspan="1" rowspan="1">Eicosanoids</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Prostaglandin C2 OR 15-deoxy-PGD2 OR other prostaglandins—8 hits</td>
<td align="left" colspan="1" rowspan="1">3.84E-02</td>
<td align="char" char="." colspan="1" rowspan="1">2.50</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Fatty Acyls</td>
<td align="left" colspan="1" rowspan="1">Eicosanoids</td>
<td align="left" colspan="1" rowspan="1">Arachidonic Acid Metabolism</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">20-Trihydroxy-leukotriene-B4 OR Aldosterone OR Cortisone</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">2.98E-02</td>
<td align="char" char="." colspan="1" rowspan="1">6.31</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Fatty Acyls OR Steroids and steroid derivatives</td>
<td align="left" colspan="1" rowspan="1">Eicosanoids OR Hydroxysteroids</td>
<td align="left" colspan="1" rowspan="1">Arachidonic acid metabolism OR Steroid hormone biosynthesis</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">TG(48:3) OR other TG—31 hits</td>
<td align="left" colspan="1" rowspan="1">3.50E-02</td>
<td align="char" char="." colspan="1" rowspan="1">1.48</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Glycerolipids</td>
<td align="left" colspan="1" rowspan="1">Triradylcglycerols</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">DG(36:3) - 2 hits</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">3.71E-02</td>
<td align="char" char="." colspan="1" rowspan="1">1.27</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Glycerolipids</td>
<td align="left" colspan="1" rowspan="1">Diradylglycerols</td>
<td align="left" colspan="1" rowspan="1">Glycerolipid metabolism</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">DG (35:0) - 3 hits</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">4.20E-02</td>
<td align="char" char="." colspan="1" rowspan="1">1.89</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Glycerolipids</td>
<td align="left" colspan="1" rowspan="1">Diradylglycerols</td>
<td align="left" colspan="1" rowspan="1">Glycerolipid metabolism</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">DG (39:1) - 3 hits</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">4.72E-02</td>
<td align="char" char="." colspan="1" rowspan="1">-1.48</td>
<td align="left" colspan="1" rowspan="1">Glycerolipids</td>
<td align="left" colspan="1" rowspan="1">Diradylglycerols</td>
<td align="left" colspan="1" rowspan="1">Glycerolipid metabolism</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">LysoPA—2 hits</td>
<td align="left" colspan="1" rowspan="1">1.38E-02</td>
<td align="char" char="." colspan="1" rowspan="1">-2.59</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Glycerophospholipids</td>
<td align="left" colspan="1" rowspan="1">Glycerophosphates</td>
<td align="left" colspan="1" rowspan="1">Glycerolipid metabolism, Glycerophospholipid metabolism</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">PA—22 hits</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">2.89E-02</td>
<td align="char" char="." colspan="1" rowspan="1">3.42</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Glycerophospholipids</td>
<td align="left" colspan="1" rowspan="1">Glycerophosphates</td>
<td align="left" colspan="1" rowspan="1">Glycerolipid metabolism, Glycerophospholipid metabolism</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">PC—7 hits</td>
<td align="left" colspan="1" rowspan="1">3.75E-02</td>
<td align="char" char="." colspan="1" rowspan="1">-11.38</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Glycerophospholipids</td>
<td align="left" colspan="1" rowspan="1">Glycerophosphocholines</td>
<td align="left" colspan="1" rowspan="1">Glycerophospholipid metabolism, Arachidonic acid metabolism, Linoleic acid metabolism, alpha-Linolenic acid metabolism</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">PC—8 hits</td>
<td align="left" colspan="1" rowspan="1">1.49E-02</td>
<td align="char" char="." colspan="1" rowspan="1">-1.39</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Glycerophospholipids</td>
<td align="left" colspan="1" rowspan="1">Glycerophosphocholines</td>
<td align="left" colspan="1" rowspan="1">Glycerophospholipid metabolism, Arachidonic acid metabolism, Linoleic acid metabolism, alpha-Linolenic acid metabolism</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">PC—9 hits</td>
<td align="left" colspan="1" rowspan="1">4.26E-02</td>
<td align="char" char="." colspan="1" rowspan="1">1.16</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Glycerophospholipids</td>
<td align="left" colspan="1" rowspan="1">Glycerophosphocholines</td>
<td align="left" colspan="1" rowspan="1">Glycerophospholipid metabolism, Arachidonic acid metabolism, Linoleic acid metabolism, alpha-Linolenic acid metabolism</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">PC OR PE—34 hits</td>
<td align="left" colspan="1" rowspan="1">2.86E-02</td>
<td align="char" char="." colspan="1" rowspan="1">-1.16</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Glycerophospholipids</td>
<td align="left" colspan="1" rowspan="1">Glycerophosphocholines OR Glycerophosphoethanolamines</td>
<td align="left" colspan="1" rowspan="1">Glycerophospholipid metabolism, Arachidonic acid metabolism, Linoleic acid metabolism, alpha-Linolenic acid metabolism</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">PC OR PE—54 hits</td>
<td align="left" colspan="1" rowspan="1">2.21E-02</td>
<td align="char" char="." colspan="1" rowspan="1">-2.00</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Glycerophospholipids</td>
<td align="left" colspan="1" rowspan="1">Glycerophosphocholines OR Glycerophosphoethanolamines</td>
<td align="left" colspan="1" rowspan="1">Glycerophospholipid metabolism, Arachidonic acid metabolism, Linoleic acid metabolism, alpha-Linolenic acid metabolism</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">PE—4 hits</td>
<td align="left" colspan="1" rowspan="1">4.61E-02</td>
<td align="char" char="." colspan="1" rowspan="1">1.22</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Glycerophospholipids</td>
<td align="left" colspan="1" rowspan="1">Glycerophosphoethanolamines</td>
<td align="left" colspan="1" rowspan="1">Glycerophospholipid metabolism, Arachidonic acid metabolism, Linoleic acid metabolism, alpha-Linolenic acid metabolism</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">PC OR PE—18 hits</td>
<td align="left" colspan="1" rowspan="1">1.63E-02</td>
<td align="char" char="." colspan="1" rowspan="1">15.43</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Glycerophospholipids</td>
<td align="left" colspan="1" rowspan="1">Glycerophosphocholines OR Glycerophosphoethanolamines</td>
<td align="left" colspan="1" rowspan="1">Glycerophospholipid metabolism, Arachidonic acid metabolism, Linoleic acid metabolism, alpha-Linolenic acid metabolism</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">PC OR PE—37 hits</td>
<td align="left" colspan="1" rowspan="1">6.95E-03</td>
<td align="char" char="." colspan="1" rowspan="1">-2.22</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Glycerophospholipids</td>
<td align="left" colspan="1" rowspan="1">Glycerophosphocholines OR Glycerophosphoethanolamines</td>
<td align="left" colspan="1" rowspan="1">Glycerophospholipid metabolism, Arachidonic acid metabolism, Linoleic acid metabolism, alpha-Linolenic acid metabolism</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">PC OR PE—39 hits</td>
<td align="left" colspan="1" rowspan="1">2.96E-02</td>
<td align="char" char="." colspan="1" rowspan="1">-1.40</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">GlycerophospholipidsV</td>
<td align="left" colspan="1" rowspan="1">Glycerophosphocholines OR Glycerophosphoethanolamines</td>
<td align="left" colspan="1" rowspan="1">Glycerophospholipid metabolism, Arachidonic acid metabolism, Linoleic acid metabolism, alpha-Linolenic acid metabolism</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">PE OR PC—39 hits</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">2.07E-02</td>
<td align="char" char="." colspan="1" rowspan="1">3.93</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Glycerophospholipids</td>
<td align="left" colspan="1" rowspan="1">Glycerophosphoethanolamines OR Glycerophosphocholines</td>
<td align="left" colspan="1" rowspan="1">Glycerophospholipid metabolism, Arachidonic acid metabolism, Linoleic acid metabolism, alpha-Linolenic acid metabolism</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">PE OR PC—58 hits</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">4.52E-02</td>
<td align="char" char="." colspan="1" rowspan="1">3.53</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Glycerophospholipids</td>
<td align="left" colspan="1" rowspan="1">Glycerophosphoethanolamines OR Glycerophosphocholines</td>
<td align="left" colspan="1" rowspan="1">Glycerophospholipid metabolism, Arachidonic acid metabolism, Linoleic acid metabolism, alpha-Linolenic acid metabolism</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">PE—3 hits</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">3.96E-02</td>
<td align="char" char="." colspan="1" rowspan="1">2.75</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Glycerophospholipids</td>
<td align="left" colspan="1" rowspan="1">Glycerophosphoethanolamines</td>
<td align="left" colspan="1" rowspan="1">Glycerophospholipid metabolism, Arachidonic acid metabolism, Linoleic acid metabolism, alpha-Linolenic acid metabolism</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">PE OR PC—16 hits</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">4.30E-02</td>
<td align="char" char="." colspan="1" rowspan="1">-1.42</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Glycerophospholipids</td>
<td align="left" colspan="1" rowspan="1">Glycerophosphocholines OR Glycerophosphocholines</td>
<td align="left" colspan="1" rowspan="1">Glycerophospholipid metabolism, Arachidonic acid metabolism, Linoleic acid metabolism, alpha-Linolenic acid metabolism</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">PE OR PC—36 hits</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">4.15E-02</td>
<td align="char" char="." colspan="1" rowspan="1">-3.61</td>
<td align="left" colspan="1" rowspan="1">2.54E-02</td>
<td align="char" char="." colspan="1" rowspan="1">9.29</td>
<td align="left" colspan="1" rowspan="1">Glycerophospholipids</td>
<td align="left" colspan="1" rowspan="1">Glycerophosphoethanolamines OR Glycerophosphocholines</td>
<td align="left" colspan="1" rowspan="1">Glycerophospholipid metabolism, Arachidonic acid metabolism, Linoleic acid metabolism, alpha-Linolenic acid metabolism</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">PA—20 hits</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">4.54E-02</td>
<td align="char" char="." colspan="1" rowspan="1">3.83</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Glycerophospholipids</td>
<td align="left" colspan="1" rowspan="1">Glycerophosphates</td>
<td align="left" colspan="1" rowspan="1">Glycerolipid metabolism, Glycerophospholipid metabolism</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">PA—24 hits</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">3.35E-02</td>
<td align="char" char="." colspan="1" rowspan="1">1.43</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Glycerophospholipids</td>
<td align="left" colspan="1" rowspan="1">Glycerophosphates</td>
<td align="left" colspan="1" rowspan="1">Glycerolipid metabolism, Glycerophospholipid metabolism</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">PS—10 hits</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">2.58E-03</td>
<td align="char" char="." colspan="1" rowspan="1">1.63</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Glycerophospholipids</td>
<td align="left" colspan="1" rowspan="1">Glycerophosphoserines</td>
<td align="left" colspan="1" rowspan="1">Glycine, serine and threonine metabolism, Glycerophospholipid metabolism</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">PS—16 hits</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">7.44E-03</td>
<td align="char" char="." colspan="1" rowspan="1">1.63</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Glycerophospholipids</td>
<td align="left" colspan="1" rowspan="1">Glycerophosphoserines</td>
<td align="left" colspan="1" rowspan="1">Glycine, serine and threonine metabolism, Glycerophospholipid metabolism</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">PS(36:8)</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">4.59E-02</td>
<td align="char" char="." colspan="1" rowspan="1">1.99</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Glycerophospholipids</td>
<td align="left" colspan="1" rowspan="1">Glycerophosphoserines</td>
<td align="left" colspan="1" rowspan="1">Glycine, serine and threonine metabolism, Glycerophospholipid metabolism</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">PC—4 hits</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">1.96E-02</td>
<td align="char" char="." colspan="1" rowspan="1">-1.25</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Glycerophospholipids</td>
<td align="left" colspan="1" rowspan="1">Glycerophosphocholines</td>
<td align="left" colspan="1" rowspan="1">Glycerophospholipid metabolism, Arachidonic acid metabolism, Linoleic acid metabolism, alpha-Linolenic acid metabolism</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">PC—20 hits</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">1.88E-02</td>
<td align="char" char="." colspan="1" rowspan="1">-5.28</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Glycerophospholipids</td>
<td align="left" colspan="1" rowspan="1">Glycerophosphocholines</td>
<td align="left" colspan="1" rowspan="1">Glycerophospholipid metabolism, Arachidonic acid metabolism, Linoleic acid metabolism, alpha-Linolenic acid metabolism</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">PE—7 hits</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">3.26E-02</td>
<td align="char" char="." colspan="1" rowspan="1">-1.82</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Glycerophospholipids</td>
<td align="left" colspan="1" rowspan="1">Glycerophosphoethanolamines</td>
<td align="left" colspan="1" rowspan="1">Glycerophospholipid metabolism, Arachidonic acid metabolism, Linoleic acid metabolism, alpha-Linolenic acid metabolism</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">PE—2 hits</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">2.30E-02</td>
<td align="char" char="." colspan="1" rowspan="1">1.02</td>
<td align="left" colspan="1" rowspan="1">Glycerophospholipids</td>
<td align="left" colspan="1" rowspan="1">Glycerophosphoethanolamines</td>
<td align="left" colspan="1" rowspan="1">Glycerophospholipid metabolism, Arachidonic acid metabolism, Linoleic acid metabolism, alpha-Linolenic acid metabolism</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Hydroxyphenylacetylglycine OR Hypoxanthine</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">4.12E-02</td>
<td align="char" char="." colspan="1" rowspan="1">2.73</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Imidazopyrimidines OR Carboxylic acids and derivatives</td>
<td align="left" colspan="1" rowspan="1">Purines and purine derivatives OR Amino acids, peptides, and analogues</td>
<td align="left" colspan="1" rowspan="1">Tyrosine metabolism OR Purine Metabolism</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Decanoylcholine</td>
<td align="left" colspan="1" rowspan="1">2.00E-02</td>
<td align="char" char="." colspan="1" rowspan="1">1.20</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Organonitrogen compounds</td>
<td align="left" colspan="1" rowspan="1">Quaternary ammonium salts</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">N-Acetyl-D-glucosaminyldiphosphodolichol</td>
<td align="left" colspan="1" rowspan="1">4.95E-02</td>
<td align="char" char="." colspan="1" rowspan="1">4.80</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Organooxygen compounds</td>
<td align="left" colspan="1" rowspan="1">Carbohydrates and carbohydrate conjugates</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">3-Sialyl-N-acetyllactosamine OR 6-Sialyl-N-acetyllactosamine</td>
<td align="left" colspan="1" rowspan="1">3.03E-02</td>
<td align="char" char="." colspan="1" rowspan="1">17.71</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Organooxygen compounds</td>
<td align="left" colspan="1" rowspan="1">Carbohydrates and carbohydrate conjugates</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Quinone</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">1.19E-02</td>
<td align="char" char="." colspan="1" rowspan="1">-1.28</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Organooxygen compounds</td>
<td align="left" colspan="1" rowspan="1">Carbonyl compounds</td>
<td align="left" colspan="1" rowspan="1">Riboflavin Metabolism, Pyrimidine Metabolism</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Spermidine monoaldehyde 1</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">4.52E-02</td>
<td align="char" char="." colspan="1" rowspan="1">1.67</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Organooxygen compounds</td>
<td align="left" colspan="1" rowspan="1">Carbonyl compounds</td>
<td align="left" colspan="1" rowspan="1">Arginine and proline metabolism, beta-Alanine metabolism, Glutathione metabolism, Bile secretion</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">N-Acetylneuraminic acid</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">3.43E-02</td>
<td align="char" char="." colspan="1" rowspan="1">3.02</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Organooxygen compounds</td>
<td align="left" colspan="1" rowspan="1">Carbohydrates and carbohydrate conjugates</td>
<td align="left" colspan="1" rowspan="1">Amino Sugar and Nucleotide Sugar Metabolism</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Hydroxyphenyllactic acid</td>
<td align="left" colspan="1" rowspan="1">1.37E-02</td>
<td align="char" char="." colspan="1" rowspan="1">2.18</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Phenylpropanoic acids</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">3-Hydroxy-4-methoxyphenyllactic acid OR other polyphenol metabolites—65 hits</td>
<td align="left" colspan="1" rowspan="1">9.39E-03</td>
<td align="char" char="." colspan="1" rowspan="1">-1.73</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Phenylpropanoic acids</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Formyl-CoA</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">4.64E-03</td>
<td align="char" char="." colspan="1" rowspan="1">6.27</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Purine nucleotides</td>
<td align="left" colspan="1" rowspan="1">Purine ribonucleotides</td>
<td align="left" colspan="1" rowspan="1">Oxidation of Branched Chain Fatty Acids, Glyoxylate and dicarboxylate metabolism</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Ceramide (42:0)</td>
<td align="left" colspan="1" rowspan="1">2.27E-02</td>
<td align="char" char="." colspan="1" rowspan="1">7.47</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Sphingolipids</td>
<td align="left" colspan="1" rowspan="1">Ceramides</td>
<td align="left" colspan="1" rowspan="1">Sphingolipid metabolism</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Ceramide (44:1)</td>
<td align="left" colspan="1" rowspan="1">1.49E-02</td>
<td align="char" char="." colspan="1" rowspan="1">2.50</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Sphingolipids</td>
<td align="left" colspan="1" rowspan="1">Ceramides</td>
<td align="left" colspan="1" rowspan="1">Sphingolipid metabolism</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Ganglioside GA2 (30:0) OR Trihexosylceramide (30:1)</td>
<td align="left" colspan="1" rowspan="1">2.24E-02</td>
<td align="char" char="." colspan="1" rowspan="1">37.00</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Sphingolipids</td>
<td align="left" colspan="1" rowspan="1">Glycosphingolipids</td>
<td align="left" colspan="1" rowspan="1">Highly important in immunology</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">SM(32:1)</td>
<td align="left" colspan="1" rowspan="1">3.41E-02</td>
<td align="char" char="." colspan="1" rowspan="1">1.20</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Sphingolipids</td>
<td align="left" colspan="1" rowspan="1">Phosphosphingolipids</td>
<td align="left" colspan="1" rowspan="1">Sphingolipid metabolism, Sphingolipid signaling pathway, Necroptosis</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Glucosylceramide (42:1)</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">4.08E-02</td>
<td align="char" char="." colspan="1" rowspan="1">1.33</td>
<td align="left" colspan="1" rowspan="1">3.70E-02</td>
<td align="char" char="." colspan="1" rowspan="1">-1.33</td>
<td align="left" colspan="1" rowspan="1">Sphingolipids</td>
<td align="left" colspan="1" rowspan="1">Glycosphingolipids</td>
<td align="left" colspan="1" rowspan="1">Sphingolipid metabolism</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Ganglioside GM3 (32:0)</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">4.19E-02</td>
<td align="char" char="." colspan="1" rowspan="1">-1.67</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Sphingolipids</td>
<td align="left" colspan="1" rowspan="1">Glycosphingolipids</td>
<td align="left" colspan="1" rowspan="1">Highly important in immunology</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Galabiosylceramide (44:1) OR Lactosylceramide (44:1)</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">3.12E-03</td>
<td align="char" char="." colspan="1" rowspan="1">2.20</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Sphingolipids</td>
<td align="left" colspan="1" rowspan="1">Glycosphingolipids</td>
<td align="left" colspan="1" rowspan="1">Sphingolipid metabolism</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Glucosylceramide (36:1) OR Galactosylceramide (36:1)</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">1.98E-02</td>
<td align="char" char="." colspan="1" rowspan="1">1.17</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Sphingolipids</td>
<td align="left" colspan="1" rowspan="1">Glycosphingolipids</td>
<td align="left" colspan="1" rowspan="1">Sphingolipid metabolism</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Ganglioside GM3 (40:2)</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">3.82E-02</td>
<td align="char" char="." colspan="1" rowspan="1">3.23</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Sphingolipids</td>
<td align="left" colspan="1" rowspan="1">Glycosphingolipids</td>
<td align="left" colspan="1" rowspan="1">Highly important in immunology</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">SM(44:1)</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">3.88E-02</td>
<td align="char" char="." colspan="1" rowspan="1">1.16</td>
<td align="left" colspan="1" rowspan="1">Sphingolipids</td>
<td align="left" colspan="1" rowspan="1">Phosphosphingolipids</td>
<td align="left" colspan="1" rowspan="1">Sphingolipid metabolism, Sphingolipid signaling pathway, Necroptosis</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">3alpha,21-Dihydroxy-5beta-pregnane-11,20-dione</td>
<td align="left" colspan="1" rowspan="1">2.76E-02</td>
<td align="char" char="." colspan="1" rowspan="1">2.41</td>
<td align="left" colspan="1" rowspan="1">3.71E-02</td>
<td align="char" char="." colspan="1" rowspan="1">1.88</td>
<td align="left" colspan="1" rowspan="1">2.00E-02</td>
<td align="char" char="." colspan="1" rowspan="1">-1.36</td>
<td align="left" colspan="1" rowspan="1">Steroids and steroid derivatives</td>
<td align="left" colspan="1" rowspan="1">Hydroxysteroids</td>
<td align="left" colspan="1" rowspan="1">Steroid hormone biosynthesis</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">17alpha,21-Dihydroxy-5beta-pregnane-3,11,20-trione OR Cortisol OR 18-Hydroxycorticosterone</td>
<td align="left" colspan="1" rowspan="1">3.06E-02</td>
<td align="char" char="." colspan="1" rowspan="1">1.53</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Steroids and steroid derivatives</td>
<td align="left" colspan="1" rowspan="1">Hydroxysteroids</td>
<td align="left" colspan="1" rowspan="1">Steroid hormone biosynthesis</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Chenodeoxycholic acid sulfate OR Chenodeoxycholic acid 3-sulfate OR Ursodeoxycholic acid 3-sulfate</td>
<td align="left" colspan="1" rowspan="1">6.18E-03</td>
<td align="char" char="." colspan="1" rowspan="1">2.29</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Steroids and steroid derivatives</td>
<td align="left" colspan="1" rowspan="1">Bile acids, alcohols and derivatives</td>
<td align="left" colspan="1" rowspan="1">Fat digestion and absorption, Vitamin digestion and absorption</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Glycoursodeoxycholic acid OR Deoxycholic acid glycine conjugate OR Chenodeoxycholic acid glycine conjugate OR Chenodeoxyglycocholic acid</td>
<td align="left" colspan="1" rowspan="1">3.48E-02</td>
<td align="char" char="." colspan="1" rowspan="1">-7.61</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Steroids and steroid derivatives</td>
<td align="left" colspan="1" rowspan="1">Bile acids, alcohols and derivatives</td>
<td align="left" colspan="1" rowspan="1">Fat digestion and absorption, Vitamin digestion and absorption</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Estrone glucuronide</td>
<td align="left" colspan="1" rowspan="1">3.97E-02</td>
<td align="char" char="." colspan="1" rowspan="1">2.09</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Steroids and steroid derivatives</td>
<td align="left" colspan="1" rowspan="1">Steroidal glycosides</td>
<td align="left" colspan="1" rowspan="1">Steroid hormone biosynthesis</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">25-Hydroxyvitamin D3-26,23-lactone</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">4.77E-02</td>
<td align="char" char="." colspan="1" rowspan="1">2.09</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Steroids and steroid derivatives</td>
<td align="left" colspan="1" rowspan="1">Vitamin D and derivatives</td>
<td align="left" colspan="1" rowspan="1">Steroid hormone biosynthesis</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Dehydroepiandrosterone 3-glucuronide OR Dehydroisoandrosterone 3-glucuronide</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">3.60E-02</td>
<td align="char" char="." colspan="1" rowspan="1">3.54</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Steroids and steroid derivatives</td>
<td align="left" colspan="1" rowspan="1">Steroidal glycosides</td>
<td align="left" colspan="1" rowspan="1">Steroid hormone biosynthesis</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">2-hydroxyethinylestradiol</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">2.51E-02</td>
<td align="char" char="." colspan="1" rowspan="1">1.34</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Steroids and steroid derivatives</td>
<td align="left" colspan="1" rowspan="1">Estrane steroids</td>
<td align="left" colspan="1" rowspan="1">Steroid hormone biosynthesis</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">5beta-Pregnanediol</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">4.32E-02</td>
<td align="char" char="." colspan="1" rowspan="1">1.03</td>
<td align="left" colspan="1" rowspan="1">Steroids and steroid derivatives</td>
<td align="left" colspan="1" rowspan="1">Pregnane steroids</td>
<td align="left" colspan="1" rowspan="1">Steroid hormone biosynthesis</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">trans-Resveratrol 4'-O-glucuronide OR cis-Resveratrol 4'-O-glucuronide</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">1.17E-02</td>
<td align="char" char="." colspan="1" rowspan="1">76.61</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Stilbenes</td>
<td align="left" colspan="1" rowspan="1">Stilbene glycosides</td>
<td align="left" colspan="1" rowspan="1">Stilbenoid, diarylheptanoid and gingerol biosynthesis</td>
</tr>
</tbody>
</table>
</alternatives>
<table-wrap-foot>
<fn id="t002fn001">
<p>FDR: false discovery rate q-value; FC: fold change.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
</sec>
<sec id="sec016" sec-type="results">
<title>Results</title>
<sec id="sec017">
<title>RUPP control vs sham control</title>
<p>Using UPLC-Q-TOF-MS, we compared metabolic profiles of RUPP rats (RC) and sham rats (SC) to identify metabolites that were altered in a rat model of pre-eclampsia. The statistical analysis comparing levels of metabolites detected in RC to SC showed that out of 15,024 detected features, 49 metabolites were significant (FDR q-value &lt; 0.05); volcano plots are presented in <xref ref-type="fig" rid="pone.0230977.g001">Fig 1A and 1B</xref>. Among these 49 metabolites, 10 were annotated through database search, and belonged in 8 chemical classes (<xref ref-type="table" rid="pone.0230977.t002">Table 2</xref>): two amino acids, peptides and analogues, one fatty acyl, one glycerolipid, two glycerophospholipids (GPL), two sphingolipids, and two steroids and steroid derivatives. All of these metabolites were detected at lower levels in RUPP control rats compared to sham rats, except for three (two GPL, and one steroid derivative). Interestingly, L-palmitoylcarnitine, a fatty acyl involved in mitochondrial respiration [<xref ref-type="bibr" rid="pone.0230977.ref038">38</xref>], was detected at lower levels in RUPP control group with a fold change of -10.35.</p>
<fig id="pone.0230977.g001" orientation="portrait" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0230977.g001</object-id>
<label>Fig 1</label>
<caption>
<title>Volcano plot of metabolomics data, showing log2 fold change plotted against log10 of FDR q-values.</title>
<p>(A) RUPP Control (RC) vs Sham Control (SC) in ESI+. (B) RUPP Control vs Sham Control in ESI-. (C) RUPP +ET (RT) vs RUPP Control in ESI+. (D) RUPP +ET vs RUPP Control in ESI-. (E) RUPP+ ET vs Sham+ET (ST) ESI+. (F) RUPP+ET vs Sham+ET ESI-. Features with FDR &lt; 0.05 are plotted in blue.</p>
</caption>
<graphic xlink:href="pone.0230977.g001"></graphic>
</fig>
</sec>
<sec id="sec018">
<title>RUPP+ET vs RUPP control</title>
<p>To identify metabolites that were altered following L-Ergothioneine treatment in the RUPP rat model of pre-eclampsia, we compared metabolic profiles of RUPP rats treated with ET (RT) to profiles of RUPP rats not treated (RC). Following statistical analysis, and out of 15,034 detected features, we reported 529 metabolites as significantly altered (FDR q-value &lt; 0.05), volcano plots are presented in <xref ref-type="fig" rid="pone.0230977.g001">Fig 1C and 1D</xref>, and 45 metabolites were annotated through database search (<xref ref-type="table" rid="pone.0230977.t002">Table 2</xref>). The metabolites annotated belonged to the following chemical classes: fourteen glycerophospholipids (GPL), eleven amino acids, peptides, and analogues, five sphingolipids, four steroid and steroid derivatives, two fatty acyls, two glycerolipids, one benzopyran, one imidazopyrimidine, three organooxygen compounds, one purine nucleotide, and one stilbene. The majority of these metabolites were detected at higher levels in the RUPP+ET group compared to RUPP control group. Out of the fourteen GPL detected, eight were phosphatidylcholines (PC) or phosphatidylethanolamines (PE), and are involved in arachidonic acid metabolism, linoleic acid metabolism, and alpha-linolenic acid metabolism. In addition, two metabolites involved in arachidonic acid metabolism were differentially detected between RT and RC: 20-Trihydroxy-leukotriene-B4, and 20-COOH-leukotriene E4. The second chemical class that showed the most altered metabolites was amino acids, peptides, and analogues, which are involved with protein catabolism, and two of these identified amino acids are involved with glutathione metabolism (Glutamylcysteine or Cysteinyl-Glutamate), and one with the malate-aspartate shuttle (L-Glutamic acid). In addition, two gangliosides were detected (Ganglioside GM3 (32:0) with a fold change of -1.67, and Ganglioside GM3 (40:2) with a fold change of 3.23).</p>
</sec>
<sec id="sec019">
<title>RUPP+ET vs Sham+ET</title>
<p>Similarly, we compared metabolic profiles of RUPP+ET to profiles of Sham+ET, and following statistical analysis of the 15,024 detected features, we reported 368 significant metabolites (FDR q-value &lt; 0.05), volcano plots are presented in <xref ref-type="fig" rid="pone.0230977.g001">Fig 1E and 1F</xref>. 50 were annotated following database search (<xref ref-type="table" rid="pone.0230977.t002">Table 2</xref>). The annotated metabolites belong in 10 chemical classes: fifteen amino acids, peptides, and analogues, ten glycerophospholipids (GPL), nine fatty acyls, five steroids and steroid derivatives, four sphingolipids, two organooxygen compounds, two phenylpropanoic acids, one benzopyran, one organonitrogen compound, and one glycerolipid. The majority of these metabolites (36) were detected at significantly higher levels in RUPP+ET group compared to Sham+ET group. Similar to the comparison of RUPP+ET to RC, among the 10 GPL detected as significanlty altered in RUPP+ET compared to Sham+ET, nine are PC or PE.</p>
<p>In addition, 20-Oxo-leukotriene E4, a metabolite of Leukotriene E4 (LTE4) following lipid oxidation, was detected at higher levels in RUPP+ET rats. Furthermore, two fatty acyls showed very high fold change in RUPP+ET compared to Sham +ET, (S)-3-Hydroxytetradecanoyl-CoA (FC 36.6) and 3-Oxotetradecanoyl-CoA (FC 85.27). Both of these fatty acids are involved with fatty acid metabolism, mitochondrial beta-oxidation of long chain saturated fatty acids, and fatty acid elongation in the mitochondria. In addition, Ganglioside GA2 (30:0) (or Trihexosylceramide (30:1)) was detected with a fold change of 37 in RUPP+ET compared to Sham+ET. Five of the amino acids and peptides detected as significantly altered between RUPP+ET and RC were also significantly altered in RUPP+ET compared to Sham+ET, most of which were detected at higher levels in RUPP+ET compared to Sham+ET, including L-Glutamic acid (FC 1.91) and Glutamylcysteine or Cysteinyl-Glutamate (FC 2.18).</p>
<p>Three metabolites were detected as significantly altered both in RUPP control vs Sham and in RUPP+ET vs RUPP control, with opposite fold changes: one GPL (a phosphatidylethanolamine or phosphatidylcholine), one sphingolipid (glucosylceramide (42:1)). One steroid derivative (3alpha,21-Dihydroxy-5beta-pregnane-11,20-dione) was detected as significantly altered in all comparisions: RUPP+ET compared to Sham+ET (FDR = 2.76E-02, FC 2.41), RUPP+ET compared to RUPP Control (FDR = 3.71E-02, FC 1.88), and RUPP Control compared to Sham Control (FDR = 2.00E-02, CF -1.36). A parallel coordinate plot showing the levels of 10 metabolites of interest in the fours experimental groups is shown in <xref ref-type="fig" rid="pone.0230977.g002">Fig 2</xref>, and demonstrates that for most of these metabolites, the levels in the RUPP+ET group are similar to those in the Sham Control group.</p>
<fig id="pone.0230977.g002" orientation="portrait" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0230977.g002</object-id>
<label>Fig 2</label>
<caption>
<title>Parallel coordinate plot showing the averaged and normalised peak intensity of ten metabolites of interest in Sham Control, Sham +ET, RUPP Control and RUPP +ET rats.</title>
</caption>
<graphic xlink:href="pone.0230977.g002"></graphic>
</fig>
<p>In addition, L-Ergothioneine and two of its metabolites (Hercynine, and S-methyl-L-Ergothioneine) were detected at similar relative levels in the plasma of all groups of animals in ESI+ (Figs <xref ref-type="fig" rid="pone.0230977.g003">3</xref> and <xref ref-type="fig" rid="pone.0230977.g004">4</xref>). This presumably reflects the fact that it is excreted only very slowly so accumulates in the tissues.</p>
<fig id="pone.0230977.g003" orientation="portrait" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0230977.g003</object-id>
<label>Fig 3</label>
<caption>
<title>Mass spectra of L-Ergothioneine (1a, 1b), L-Hercynine (2a, 2b), and S-methyL-Ergothioneine (3a, 3b), detected in ESI+ mode using UPLC-Q-TOF-MS analysis.</title>
<p>Spectra show m/z and intensity of peaks detected. 1a: MS1 scan showing parent ion of L-Ergothioneine at 228.0766 m/z, and 1b: MS2 scan showing its product ion at 127.0641 m/z; 2a: MS1 scan showing parent ion of L-Hercynine at 198.1989 m/z, and 2b: MS2 scan showing its product ion at 95.0938 m/z; 3a: MS1 scan showing parent ion of S-methyL-Ergothioneine at 244.1528 m/z, and 3b: MS2 scan showing its product ion at 141.0808m/z.</p>
</caption>
<graphic xlink:href="pone.0230977.g003"></graphic>
</fig>
<fig id="pone.0230977.g004" orientation="portrait" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0230977.g004</object-id>
<label>Fig 4</label>
<caption>
<title>Plasma levels of L-Ergothioneine (A), Hercynine (B), and S-methyl- L-Ergothioneine (C).</title>
<p>Levels are shown as normalised intensity as detected in ESI+ UPLC-Q-TOF-MS in plasma samples of RUPP Control, RUUP +ET, Sham Control and Sham +ET groups. No significant differences in levels observed between the groups. All values are expressed with standard error.</p>
</caption>
<graphic xlink:href="pone.0230977.g004"></graphic>
</fig>
</sec>
</sec>
<sec id="sec020" sec-type="conclusions">
<title>Discussion</title>
<p>The present study showed evidence of mitochondrial dysfunction in the plasma metabolite profile in the RUPP rat model of pre-eclampsia. This was evident from the lower levels of L-palmitoylcarnitine in RUPP+ET compared to RUPP Control (FC -10.35), which is associated with beta-oxidation in the mitochondria; from the higher levels of 3-Hydroxytetradecanoyl-CoA (FC 36.6) and 3-Oxotetradecanoyl-CoA (FC 85.27) in RUPP+ET compared to Sham+ET; and from the detection of several significantly altered sphingolipids, which are involved in various cellular processes, such as apoptosis and inflammation [<xref ref-type="bibr" rid="pone.0230977.ref039">39</xref>–<xref ref-type="bibr" rid="pone.0230977.ref041">41</xref>].</p>
<p>This study showed that L- palmitoylcarnitine was detected at significantly lower levels in RUPP Control compared to Sham Control rats (FC -10.35). Under physiological conditions, the mitochondria uses oxidative phosphorylation and the electron transport chain to produce ATP. However, it has been shown that pre-eclampsia is associated with mitochondrial dysfunction and oxidative stress [<xref ref-type="bibr" rid="pone.0230977.ref013">13</xref>, <xref ref-type="bibr" rid="pone.0230977.ref042">42</xref>], and under such conditions, it is hypothesied that L- palmitoylcarnitine could be used as a mediator of mitochondrial respiration which could explain its lower levels in the RUPP Control rats, a model for pre-eclampsia, compared to healthy Sham Control rats. It has been shown that RUPP rats have increased evidence of mitochondrial dysfunction compared to sham controls [<xref ref-type="bibr" rid="pone.0230977.ref011">11</xref>, <xref ref-type="bibr" rid="pone.0230977.ref022">22</xref>]. Williamson <italic>et al</italic>. have recently shown <italic>in vivo</italic> that mitochondrial-specific production of H<sub>2</sub>O<sub>2</sub> in kidney tissue is increased in RUPP rats compared to sham control rats [<xref ref-type="bibr" rid="pone.0230977.ref043">43</xref>], which further demonstrated that mitochondrial dysfunction is associated with the pathophysiology of pre-eclampsia. This study also showed that the RUPP rats treated with ET (RUPP+ET) presented altered levels of fourteen glycerophospholipids (GPL) compared to RUPP rats (RC). Eight of these GPL are part of the arachidonic acid, linoleic acid, and alpha-linolenic acid metabolism pathways, which are used as precursors in the biosynthesis of several metabolites, such as eicosanoids or prostaglandins, involved in multiple cellular processes, including inflammation [<xref ref-type="bibr" rid="pone.0230977.ref039">39</xref>]. Here, we reported that five of these metabolites were detected at lower levels in RT rats compared to RC rats, demonstrating the anti-inflammatory effects of ET in the RUPP rat model of pre-eclampsia. In addition, L-glutamic acid was detected at higher levels in RT rats compared to RC. This amino acid is involved in the malate-aspartate shuttle system, or the malate shuttle, which is an essential system used by functional mitochondria allowing electrons to effectively move across the impermeable membrane between the cytoplasm and the mitochondrial matrix. Another metabolite of interest detected at higher levels in RUPP+ET rats is glutamylcysteine. This dipeptide is associated with glutathione metabolism, and a precursor of glutathione (GSH), an antioxidant and free radical scavenger [<xref ref-type="bibr" rid="pone.0230977.ref044">44</xref>]. Taken together, higher levels of glutamylcysteine in RUPP+ET rats indicates that ET can elevate antioxidant activity in the RUPP model of pre-eclampsia. One detected metabolite was annotated for glutathione, however it was not dected as significantly altered between the four experimental groups. We can hypothesise that L-Ergothioneine treatment in the RUPP rats helps alleviate oxidative stress by using a pathway alternative to glutathione, which is in line with the discovery of a solute carrier dedicated to the transport of L-Ergothioneine, solute carrier family 22 member 4 (SLC22A4) [<xref ref-type="bibr" rid="pone.0230977.ref017">17</xref>].</p>
<p>Furthermore, this study showed that two fatty acyls were detected as significantly altered and with very high fold change in RUPP+ET compared to Sham+ET, (S)-3-Hydroxytetradecanoyl-CoA (FC 36.6) and 3-Oxotetradecanoyl-CoA (FC 85.27). Both of these fatty acyls are involved with fatty acid metabolism, mitochondrial beta-oxidation of long chain saturated fatty acids, and fatty acid elongation in the mitochondria, and further the hypothesis of mitochondrial dysfunction during pre-eclampsia [<xref ref-type="bibr" rid="pone.0230977.ref011">11</xref>–<xref ref-type="bibr" rid="pone.0230977.ref013">13</xref>]. Two metabolites involved in arachidonic acid or linoleic acid metabolism pathways were significantly elevated in RUPP+ET compared to Sham+ET: Prostaglandin C2, 13-Hydroxyoctadecadienoic acid (13-HODE). In addition, Ganglioside GA2 (30:0) (or Trihexosylceramide (30:1)), was detected with a fold change of 37 in RUPP+ET compared to Sham+ET. Taken together, the significant alterations observed when comparing RUPP+ET to RUPP Control, and RUPP+ET to Sham Control tend to confirm the effects of L-Ergothioneine on oxidative stress and inflammatory response.</p>
<p>The low number of samples per rat groups (n = 5) is a limitation of the present study. However, the experiments were designed to obtain good quality data with the use of quality control samples and analysing the samples in a randomised order, as is recommended by metabolomics guidelines [<xref ref-type="bibr" rid="pone.0230977.ref045">45</xref>]. In addition, this study showed that metabolic profiling of plasma from RUPP rat model of pre-eclampsia was able to detect pathways altered by L-Ergothioneine treatment.</p>
<p>A previous metabolomics study aiming to identify early biomarkers of prediction of small for gestational age was performed on plasma samples taken from RUPP rats, human cord blood, and human maternal plasma sample collected at 15 weeks of gestation [<xref ref-type="bibr" rid="pone.0230977.ref046">46</xref>]. In this study, Horgan <italic>et al</italic>. aimed to validate in RUPP samples the panel of potential metabolite biomarker determined in human samples. Doing so, they confirmed eleven out of nineteen metabolites were also significantly altered in RUPP plasma samples. This panel includes an amino acid, a carnitine or vitamin D derivative, a fatty acid, a glycerolipid, and four glycerophospholipids. The majority of these metabolites were detected at higher levels in RUPP samples than in control rat samples. In our study, we observed that similar metabolite classes were significantly altered when comparing RUPP Control to Sham Control, and RUPP+ET to Sham+ET profiles. However, these metabolites show opposite trends in our study compared to what Horgan <italic>et al</italic>. reported. This said, these two studies were designed with major differences. Horgan <italic>et al</italic>. focused on small for gestational age and only reported metabolites in RUPP plasma samples, while in our study we focused on the pre-eclampsia phenotype and reported the metabolites significantly altered between RUPP control and Sham control, as well as after treatment with L-Ergothioneine by comparing profiles of RUPP+ET to RUPP control, and RUPP+ET to Sham+ET.</p>
<p>The strength of our data compared to previous studies investigating the pharmacological properties of L-Ergothioneine is that we examined its effects in the RUPP rat model of pre-eclampsia, and not only in healthy subjects as previously reported [<xref ref-type="bibr" rid="pone.0230977.ref018">18</xref>, <xref ref-type="bibr" rid="pone.0230977.ref047">47</xref>]. The data presented in this study correlate with data previously reported by Cheah <italic>et al</italic>. [<xref ref-type="bibr" rid="pone.0230977.ref018">18</xref>] and Tang <italic>et al</italic>. [<xref ref-type="bibr" rid="pone.0230977.ref048">48</xref>], where both precursor ion and daughter fragment ions of L-Ergothioneine, Hercynine, and S-methyl-L-Ergothioneine were detected; however, there were no significant differences between the plasma levels in all groups in the present study. As previously reported, L-Ergothioneine accumulates in various organs and tissues in animals [<xref ref-type="bibr" rid="pone.0230977.ref016">16</xref>], including humans [<xref ref-type="bibr" rid="pone.0230977.ref018">18</xref>], especially in the liver, as well as in kidney, heart, spleen, intestines, eye, and brain tissues [<xref ref-type="bibr" rid="pone.0230977.ref048">48</xref>]. It has been reported that both brain tissue and urine from newborns contain L-Ergothioneine [<xref ref-type="bibr" rid="pone.0230977.ref049">49</xref>, <xref ref-type="bibr" rid="pone.0230977.ref050">50</xref>], which implies this molecule is able to cross the blood-placental barrier [<xref ref-type="bibr" rid="pone.0230977.ref043">43</xref>]. A neuroprotective role for L-Ergothioneine has also been suggested by a number of <italic>in vitro</italic> and <italic>in vivo</italic> studies [<xref ref-type="bibr" rid="pone.0230977.ref043">43</xref>] however, more studies are needed to determine the effects on the newborns. Administration of pure L-Ergothioneine to animals [<xref ref-type="bibr" rid="pone.0230977.ref047">47</xref>] or healthy human subjects [<xref ref-type="bibr" rid="pone.0230977.ref018">18</xref>] has shown no adverse effects, and there is thus great potential to use this naturally occurring amino acid as a potential treatment for pre-eclampsia in a clinical trial.</p>
<p>In recent years, metabolomics techniques have become crucial tools in drug discovery [<xref ref-type="bibr" rid="pone.0230977.ref051">51</xref>]. A number of recent metabolomic alterations detected in pathologies, such as Alzheimer’s diseases [<xref ref-type="bibr" rid="pone.0230977.ref052">52</xref>], frailty [<xref ref-type="bibr" rid="pone.0230977.ref053">53</xref>], atherosclerosis [<xref ref-type="bibr" rid="pone.0230977.ref054">54</xref>], cardiovascular disease [<xref ref-type="bibr" rid="pone.0230977.ref021">21</xref>], or autism and schizophrenia [<xref ref-type="bibr" rid="pone.0230977.ref055">55</xref>], have led to new hypotheses on their aetiologies and new drug targets. The study of pathologies using metabolomics approaches allows for the detection of elevated or lower levels of specific metabolites, which are regulated by enzymes for either biosynthesis or used as a substrate in a biochemical reaction, and these enzymes can be targeted and new drug treatments can be tested [<xref ref-type="bibr" rid="pone.0230977.ref051">51</xref>].</p>
<p>In conclusion, L-Ergothioneine may mediate its therapeutics properties in part by preserving mitochondrial function, increasing antioxidant levels in addition to dampening the inflammatory response evident in pre-eclampsia. Furthermore, this study highlights the potential of L-Ergothioneine as a possible treatment for pre-eclampsia.</p>
</sec>
<sec id="sec021" sec-type="supplementary-material">
<title>Supporting information</title>
<supplementary-material content-type="local-data" id="pone.0230977.s001">
<label>S1 Table</label>
<caption>
<title>Compound measurement table for UPLC-MS positive mode analysis.</title>
<p>(XLSX)</p>
</caption>
<media xlink:href="pone.0230977.s001.xlsx">
<caption>
<p>Click here for additional data file.</p>
</caption>
</media>
</supplementary-material>
<supplementary-material content-type="local-data" id="pone.0230977.s002">
<label>S2 Table</label>
<caption>
<title>Compound measurements table for UPLC-MS negative mode analysis.</title>
<p>(XLSX)</p>
</caption>
<media xlink:href="pone.0230977.s002.xlsx">
<caption>
<p>Click here for additional data file.</p>
</caption>
</media>
</supplementary-material>
</sec>
</body>
<back>
<ref-list>
<title>References</title>
<ref id="pone.0230977.ref001">
<label>1</label>
<mixed-citation publication-type="journal"><name><surname>Mol</surname><given-names>BWJ</given-names></name>, <name><surname>Roberts</surname><given-names>CT</given-names></name>, <name><surname>Thangaratinam</surname><given-names>S</given-names></name>, <name><surname>Magee</surname><given-names>LA</given-names></name>, <name><surname>de Groot</surname><given-names>CJM</given-names></name>, <name><surname>Hofmeyr</surname><given-names>GJ</given-names></name>. <article-title>Pre-eclampsia</article-title>. <source/>The Lancet. <year>2016</year>;<volume>387</volume>(<issue>10022</issue>):<fpage>999</fpage>–<lpage>1011</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(15)00070-7</pub-id>.</mixed-citation>
</ref>
<ref id="pone.0230977.ref002">
<label>2</label>
<mixed-citation publication-type="journal"><name><surname>Brown</surname><given-names>MA</given-names></name>, <name><surname>Magee</surname><given-names>LA</given-names></name>, <name><surname>Kenny</surname><given-names>LC</given-names></name>, <name><surname>Karumanchi</surname><given-names>SA</given-names></name>, <name><surname>McCarthy</surname><given-names>FP</given-names></name>, <name><surname>Saito</surname><given-names>S</given-names></name>, <etal>et al</etal>
<article-title>The hypertensive disorders of pregnancy: ISSHP classification, diagnosis &amp; management recommendations for international practice</article-title>. <source/>Pregnancy Hypertension. <year>2018</year>;<volume>13</volume>:<fpage>291</fpage>–<lpage>310</lpage>. <pub-id pub-id-type="doi">10.1016/j.preghy.2018.05.004</pub-id>. <pub-id pub-id-type="pmid">29803330</pub-id></mixed-citation>
</ref>
<ref id="pone.0230977.ref003">
<label>3</label>
<mixed-citation publication-type="journal"><name><surname>Redman</surname><given-names>CWG</given-names></name>, <name><surname>Sargent</surname><given-names>IL</given-names></name>. <article-title>Placental Stress and Pre-eclampsia: A Revised View</article-title>. <source/>Placenta. <year>2009</year>;<volume>30</volume>:<fpage>38</fpage>–<lpage>42</lpage>. <pub-id pub-id-type="doi">10.1016/j.placenta.2008.11.021</pub-id>.</mixed-citation>
</ref>
<ref id="pone.0230977.ref004">
<label>4</label>
<mixed-citation publication-type="journal"><name><surname>Redman</surname><given-names>CWG</given-names></name>, <name><surname>Staff</surname><given-names>AC</given-names></name>. <article-title>Preeclampsia, biomarkers, syncytiotrophoblast stress, and placental capacity</article-title>. <source/>American Journal of Obstetrics and Gynecology. <year>2015</year>;<volume>213</volume>(<issue>4</issue>):<fpage>S9.e1</fpage>–<lpage>S9.e4</lpage>. <pub-id pub-id-type="doi">10.1016/j.ajog.2015.08.003</pub-id>.<pub-id pub-id-type="pmid">26428507</pub-id></mixed-citation>
</ref>
<ref id="pone.0230977.ref005">
<label>5</label>
<mixed-citation publication-type="journal"><name><surname>Kenny</surname><given-names>LC</given-names></name>, <name><surname>Kell</surname><given-names>DB</given-names></name>. <article-title>Immunological tolerance, pregnancy, and preeclampsia: the roles of semen microbes and the father</article-title>. <source/>Frontiers in medicine. <year>2018</year>;<volume>4</volume>:<fpage>239</fpage>
<pub-id pub-id-type="doi">10.3389/fmed.2017.00239</pub-id>
<pub-id pub-id-type="pmid">29354635</pub-id></mixed-citation>
</ref>
<ref id="pone.0230977.ref006">
<label>6</label>
<mixed-citation publication-type="journal"><name><surname>Kell</surname><given-names>DB</given-names></name>, <name><surname>Kenny</surname><given-names>LC</given-names></name>. <article-title>A Dormant Microbial Component in the Development of Preeclampsia</article-title>. <source/>Frontiers in Medicine. <year>2016</year>;<volume>3</volume>(<issue>60</issue>). <pub-id pub-id-type="doi">10.3389/fmed.2016.00060</pub-id>
<pub-id pub-id-type="pmid">27965958</pub-id></mixed-citation>
</ref>
<ref id="pone.0230977.ref007">
<label>7</label>
<mixed-citation publication-type="journal"><name><surname>Matsubara</surname><given-names>K</given-names></name>, <name><surname>Higaki</surname><given-names>T</given-names></name>, <name><surname>Matsubara</surname><given-names>Y</given-names></name>, <name><surname>Nawa</surname><given-names>A</given-names></name>. <article-title>Nitric oxide and reactive oxygen species in the pathogenesis of preeclampsia</article-title>. <source/>International journal of molecular sciences. <year>2015</year>;<volume>16</volume>(<issue>3</issue>):<fpage>4600</fpage>–<lpage>14</lpage>. <pub-id pub-id-type="doi">10.3390/ijms16034600</pub-id>
<pub-id pub-id-type="pmid">25739077</pub-id></mixed-citation>
</ref>
<ref id="pone.0230977.ref008">
<label>8</label>
<mixed-citation publication-type="journal"><name><surname>Sánchez-Aranguren</surname><given-names>LC</given-names></name>, <name><surname>Prada</surname><given-names>CE</given-names></name>, <name><surname>Riaño-Medina</surname><given-names>CE</given-names></name>, <name><surname>Lopez</surname><given-names>M</given-names></name>. <article-title>Endothelial dysfunction and preeclampsia: role of oxidative stress</article-title>. <source/>Frontiers in physiology. <year>2014</year>;<volume>5</volume>:<fpage>372</fpage>
<pub-id pub-id-type="doi">10.3389/fphys.2014.00372</pub-id>
<pub-id pub-id-type="pmid">25346691</pub-id></mixed-citation>
</ref>
<ref id="pone.0230977.ref009">
<label>9</label>
<mixed-citation publication-type="journal"><name><surname>Birben</surname><given-names>E</given-names></name>, <name><surname>Sahiner</surname><given-names>UM</given-names></name>, <name><surname>Sackesen</surname><given-names>C</given-names></name>, <name><surname>Erzurum</surname><given-names>S</given-names></name>, <name><surname>Kalayci</surname><given-names>O</given-names></name>. <article-title>Oxidative stress and antioxidant defense</article-title>. <source/>World Allergy Organization Journal. <year>2012</year>;<volume>5</volume>(<issue>1</issue>):<fpage>9</fpage>
<pub-id pub-id-type="doi">10.1097/WOX.0b013e3182439613</pub-id>
<pub-id pub-id-type="pmid">23268465</pub-id></mixed-citation>
</ref>
<ref id="pone.0230977.ref010">
<label>10</label>
<mixed-citation publication-type="journal"><name><surname>Sedeek</surname><given-names>M</given-names></name>, <name><surname>Gilbert</surname><given-names>JS</given-names></name>, <name><surname>LaMarca</surname><given-names>BB</given-names></name>, <name><surname>Sholook</surname><given-names>M</given-names></name>, <name><surname>Chandler</surname><given-names>DL</given-names></name>, <name><surname>Wang</surname><given-names>Y</given-names></name>, <etal>et al</etal>
<article-title>Role of Reactive Oxygen Species in Hypertension Produced by Reduced Uterine Perfusion in Pregnant Rats</article-title>. <source/>American Journal of Hypertension. <year>2008</year>;<volume>21</volume>(<issue>10</issue>):<fpage>1152</fpage>–<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1038/ajh.2008.239</pub-id>
<pub-id pub-id-type="pmid">18670418</pub-id></mixed-citation>
</ref>
<ref id="pone.0230977.ref011">
<label>11</label>
<mixed-citation publication-type="journal"><name><surname>Vaka</surname><given-names>VR</given-names></name>, <name><surname>McMaster</surname><given-names>KM</given-names></name>, <name><surname>Cunningham</surname><given-names>MW</given-names><suffix>Jr</suffix></name>., <name><surname>Ibrahim</surname><given-names>T</given-names></name>, <name><surname>Hazlewood</surname><given-names>R</given-names></name>, <name><surname>Usry</surname><given-names>N</given-names></name>, <etal>et al</etal>
<article-title>Role of Mitochondrial Dysfunction and Reactive Oxygen Species in Mediating Hypertension in the Reduced Uterine Perfusion Pressure Rat Model of Preeclampsia</article-title>. <source/>Hypertension (Dallas, Tex: 1979). <year>2018</year>;<volume>72</volume>(<issue>3</issue>):<fpage>703</fpage>–<lpage>11</lpage>. <pub-id pub-id-type="doi">10.1161/HYPERTENSIONAHA.118.11290</pub-id> .<pub-id pub-id-type="pmid">30012871</pub-id></mixed-citation>
</ref>
<ref id="pone.0230977.ref012">
<label>12</label>
<mixed-citation publication-type="journal"><name><surname>McCarthy</surname><given-names>C</given-names></name>, <name><surname>Kenny</surname><given-names>LC</given-names></name>. <article-title>Therapeutically targeting mitochondrial redox signalling alleviates endothelial dysfunction in preeclampsia</article-title>. <source/>Scientific reports. <year>2016</year>;<volume>6</volume>:<fpage>32683</fpage>
<pub-id pub-id-type="doi">10.1038/srep32683</pub-id>
<pub-id pub-id-type="pmid">27604418</pub-id></mixed-citation>
</ref>
<ref id="pone.0230977.ref013">
<label>13</label>
<mixed-citation publication-type="journal"><name><surname>Williamson</surname><given-names>RD</given-names></name>, <name><surname>McCarthy</surname><given-names>FP</given-names></name>, <name><surname>Khashan</surname><given-names>AS</given-names></name>, <name><surname>Totorika</surname><given-names>A</given-names></name>, <name><surname>Kenny</surname><given-names>LC</given-names></name>, <name><surname>McCarthy</surname><given-names>C</given-names></name>. <article-title>Exploring the role of mitochondrial dysfunction in the pathophysiology of pre-eclampsia</article-title>. <source/>Pregnancy hypertension. <year>2018</year>;<volume>13</volume>:<fpage>248</fpage>–<lpage>53</lpage>. <pub-id pub-id-type="doi">10.1016/j.preghy.2018.06.012</pub-id>
<pub-id pub-id-type="pmid">30177060</pub-id></mixed-citation>
</ref>
<ref id="pone.0230977.ref014">
<label>14</label>
<mixed-citation publication-type="journal"><name><surname>Tanret</surname><given-names>C</given-names></name>. <article-title>Sur une base nouvelle retiree du seigle ergote, l’ergothioneine</article-title>. <source/>Compt Rend. <year>1909</year>:<fpage>222</fpage>–<lpage>4</lpage>.</mixed-citation>
</ref>
<ref id="pone.0230977.ref015">
<label>15</label>
<mixed-citation publication-type="journal"><name><surname>Borodina</surname><given-names>I KL</given-names></name>, <name><surname>McCarthy</surname><given-names>CM</given-names></name>, <name><surname>Paramasivan</surname><given-names>K</given-names></name>, <name><surname>Pretorius</surname><given-names>R</given-names></name>, <name><surname>Roberts</surname><given-names>TJ</given-names></name>, <name><surname>van der Hoek</surname><given-names>SA</given-names></name>, <etal>et al</etal>
<article-title>The biology of ergothioneine, an antioxidant nutraceutical</article-title>. <source/>Nutrition Research Reviews. <year>2019</year>;in press.</mixed-citation>
</ref>
<ref id="pone.0230977.ref016">
<label>16</label>
<mixed-citation publication-type="journal"><name><surname>Cheah</surname><given-names>IK</given-names></name>, <name><surname>Halliwell</surname><given-names>B</given-names></name>. <article-title>Ergothioneine; antioxidant potential, physiological function and role in disease</article-title>. <source/>Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease. <year>2012</year>;<volume>1822</volume>(<issue>5</issue>):<fpage>784</fpage>–<lpage>93</lpage>.<pub-id pub-id-type="pmid">22001064</pub-id></mixed-citation>
</ref>
<ref id="pone.0230977.ref017">
<label>17</label>
<mixed-citation publication-type="journal"><name><surname>Schomig</surname><given-names>E</given-names></name>. <article-title>Discovery of the ergothioneine transporter</article-title>. <source/>Proc Natl Acad Sci USA. <year>2005</year>;<volume>102</volume>:<fpage>5256</fpage>–<lpage>61</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0408624102</pub-id>
<pub-id pub-id-type="pmid">15795384</pub-id></mixed-citation>
</ref>
<ref id="pone.0230977.ref018">
<label>18</label>
<mixed-citation publication-type="journal"><name><surname>Cheah</surname><given-names>IK</given-names></name>, <name><surname>Tang</surname><given-names>RM</given-names></name>, <name><surname>Yew</surname><given-names>TS</given-names></name>, <name><surname>Lim</surname><given-names>KH</given-names></name>, <name><surname>Halliwell</surname><given-names>B</given-names></name>. <article-title>Administration of pure ergothioneine to healthy human subjects: Uptake, metabolism, and effects on biomarkers of oxidative damage and inflammation</article-title>. <source/>Antioxidants &amp; redox signaling. <year>2017</year>;<volume>26</volume>(<issue>5</issue>):<fpage>193</fpage>–<lpage>206</lpage>.<pub-id pub-id-type="pmid">27488221</pub-id></mixed-citation>
</ref>
<ref id="pone.0230977.ref019">
<label>19</label>
<mixed-citation publication-type="journal"><name><surname>Cheah</surname><given-names>IK</given-names></name>, <name><surname>Tang</surname><given-names>R</given-names></name>, <name><surname>Ye</surname><given-names>P</given-names></name>, <name><surname>Yew</surname><given-names>TS</given-names></name>, <name><surname>Lim</surname><given-names>KH</given-names></name>, <name><surname>Halliwell</surname><given-names>B</given-names></name>. <article-title>Liver ergothioneine accumulation in a guinea pig model of non-alcoholic fatty liver disease. A possible mechanism of defence?</article-title>
<source/>Free radical research. <year>2016</year>;<volume>50</volume>(<issue>1</issue>):<fpage>14</fpage>–<lpage>25</lpage>. <pub-id pub-id-type="doi">10.3109/10715762.2015.1099642</pub-id>
<pub-id pub-id-type="pmid">26634964</pub-id></mixed-citation>
</ref>
<ref id="pone.0230977.ref020">
<label>20</label>
<mixed-citation publication-type="journal"><name><surname>Kawano</surname><given-names>H</given-names></name>, <name><surname>Otani</surname><given-names>M</given-names></name>, <name><surname>Takeyama</surname><given-names>K</given-names></name>, <name><surname>Kawai</surname><given-names>Y</given-names></name>, <name><surname>Mayumi</surname><given-names>T</given-names></name>, <name><surname>Hama</surname><given-names>T</given-names></name>. <article-title>Studies on ergothioneine. VI. Distribution and fluctuations of ergothioneine in rats</article-title>. <source/>Chemical and pharmaceutical bulletin. <year>1982</year>;<volume>30</volume>(<issue>5</issue>):<fpage>1760</fpage>–<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1248/cpb.30.1760</pub-id>
<pub-id pub-id-type="pmid">7116510</pub-id></mixed-citation>
</ref>
<ref id="pone.0230977.ref021">
<label>21</label>
<mixed-citation publication-type="journal"><name><surname>Smith</surname><given-names>E</given-names></name>, <name><surname>Ottosson</surname><given-names>F</given-names></name>, <name><surname>Hellstrand</surname><given-names>S</given-names></name>, <name><surname>Ericson</surname><given-names>U</given-names></name>, <name><surname>Orho-Melander</surname><given-names>M</given-names></name>, <name><surname>Fernandez</surname><given-names>C</given-names></name>, <etal>et al</etal>
<article-title>Ergothioneine is associated with reduced mortality and decreased risk of cardiovascular disease</article-title>. <source/>Heart. <year>2019</year>.</mixed-citation>
</ref>
<ref id="pone.0230977.ref022">
<label>22</label>
<mixed-citation publication-type="journal"><name><surname>Williamson Rachel</surname><given-names>D</given-names></name>, <name><surname>McCarthy Fergus</surname><given-names>P</given-names></name>, <name><surname>Manna</surname><given-names>S</given-names></name>, <name><surname>Groarke</surname><given-names>E</given-names></name>, <name><surname>Kell Douglas</surname><given-names>B</given-names></name>, <name><surname>Kenny Louise</surname><given-names>C</given-names></name>, <etal>et al</etal>
<article-title>L-(+)-Ergothioneine Significantly Improves the Clinical Characteristics of Preeclampsia in the Reduced Uterine Perfusion Pressure Rat Model</article-title>. <source/>Hypertension. <year>2020</year>;<volume>75</volume>(<issue>2</issue>):<fpage>561</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1161/HYPERTENSIONAHA.119.13929</pub-id>
<pub-id pub-id-type="pmid">31865793</pub-id></mixed-citation>
</ref>
<ref id="pone.0230977.ref023">
<label>23</label>
<mixed-citation publication-type="journal"><name><surname>Granger</surname><given-names>JP</given-names></name>, <name><surname>LaMarca</surname><given-names>BB</given-names></name>, <name><surname>Cockrell</surname><given-names>K</given-names></name>, <name><surname>Sedeek</surname><given-names>M</given-names></name>, <name><surname>Balzi</surname><given-names>C</given-names></name>, <name><surname>Chandler</surname><given-names>D</given-names></name>, <etal>et al</etal>
<article-title>Reduced uterine perfusion pressure (RUPP) model for studying cardiovascular-renal dysfunction in response to placental ischemia</article-title>. <source/>Methods Mol Med. <year>2006</year>;<volume>122</volume>:<fpage>383</fpage>–<lpage>92</lpage>. Epub 2006/03/04. <pub-id pub-id-type="doi">10.1385/1-59259-989-3:381</pub-id> .<pub-id pub-id-type="pmid">16511995</pub-id></mixed-citation>
</ref>
<ref id="pone.0230977.ref024">
<label>24</label>
<mixed-citation publication-type="journal"><name><surname>McCarthy</surname><given-names>FP</given-names></name>, <name><surname>Drewlo</surname><given-names>S</given-names></name>, <name><surname>Kingdom</surname><given-names>J</given-names></name>, <name><surname>Johns</surname><given-names>EJ</given-names></name>, <name><surname>Walsh</surname><given-names>SK</given-names></name>, <name><surname>Kenny</surname><given-names>LC</given-names></name>. <article-title>Peroxisome proliferator-activated receptor-gamma as a potential therapeutic target in the treatment of preeclampsia</article-title>. <source/>Hypertension. <year>2011</year>;<volume>58</volume>(<issue>2</issue>):<fpage>280</fpage>–<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1161/HYPERTENSIONAHA.111.172627</pub-id> .<pub-id pub-id-type="pmid">21690483</pub-id></mixed-citation>
</ref>
<ref id="pone.0230977.ref025">
<label>25</label>
<mixed-citation publication-type="journal"><name><surname>Sakrak</surname><given-names>O</given-names></name>, <name><surname>Kerem</surname><given-names>M</given-names></name>, <name><surname>Bedirli</surname><given-names>A</given-names></name>, <name><surname>Pasaoglu</surname><given-names>H</given-names></name>, <name><surname>Akyurek</surname><given-names>N</given-names></name>, <name><surname>Ofluoglu</surname><given-names>E</given-names></name>, <etal>et al</etal>
<article-title>Ergothioneine modulates proinflammatory cytokines and heat shock protein 70 in mesenteric ischemia and reperfusion injury</article-title>. <source/>The Journal of surgical research. <year>2008</year>;<volume>144</volume>(<issue>1</issue>):<fpage>36</fpage>–<lpage>42</lpage>. Epub 2007/07/03. <pub-id pub-id-type="doi">10.1016/j.jss.2007.04.020</pub-id> .<pub-id pub-id-type="pmid">17603080</pub-id></mixed-citation>
</ref>
<ref id="pone.0230977.ref026">
<label>26</label>
<mixed-citation publication-type="journal"><name><surname>Deiana</surname><given-names>M</given-names></name>, <name><surname>Rosa</surname><given-names>A</given-names></name>, <name><surname>Casu</surname><given-names>V</given-names></name>, <name><surname>Piga</surname><given-names>R</given-names></name>, <name><surname>Assunta Dessi</surname><given-names>M</given-names></name>, <name><surname>Aruoma</surname><given-names>OI</given-names></name>. <article-title>L-ergothioneine modulates oxidative damage in the kidney and liver of rats in vivo: studies upon the profile of polyunsaturated fatty acids</article-title>. <source/>Clinical nutrition (Edinburgh, Scotland). <year>2004</year>;<volume>23</volume>(<issue>2</issue>):<fpage>183</fpage>–<lpage>93</lpage>. Epub 2004/03/20. <pub-id pub-id-type="doi">10.1016/s0261-5614(03)00108-0</pub-id> .<pub-id pub-id-type="pmid">15030958</pub-id></mixed-citation>
</ref>
<ref id="pone.0230977.ref027">
<label>27</label>
<mixed-citation publication-type="journal"><name><surname>Dunn</surname><given-names>WB</given-names></name>, <name><surname>Broadhurst</surname><given-names>D</given-names></name>, <name><surname>Begley</surname><given-names>P</given-names></name>, <name><surname>Zelena</surname><given-names>E</given-names></name>, <name><surname>Francis-McIntyre</surname><given-names>S</given-names></name>, <name><surname>Anderson</surname><given-names>N</given-names></name>, <etal>et al</etal>
<article-title>Procedures for large-scale metabolic profiling of serum and plasma using gas chromatography and liquid chromatography coupled to mass spectrometry</article-title>. <source/>Nature protocols. <year>2011</year>;<volume>6</volume>(<issue>7</issue>):<fpage>1060</fpage>–<lpage>83</lpage>. <pub-id pub-id-type="doi">10.1038/nprot.2011.335</pub-id>
<pub-id pub-id-type="pmid">21720319</pub-id></mixed-citation>
</ref>
<ref id="pone.0230977.ref028">
<label>28</label>
<mixed-citation publication-type="journal"><name><surname>Bateman</surname><given-names>R</given-names></name>, <name><surname>Carruthers</surname><given-names>R</given-names></name>, <name><surname>Hoyes</surname><given-names>J</given-names></name>, <name><surname>Jones</surname><given-names>C</given-names></name>, <name><surname>Langridge</surname><given-names>J</given-names></name>, <name><surname>Millar</surname><given-names>A</given-names></name>, <etal>et al</etal>
<article-title>A novel precursor ion discovery method on a hybrid quadrupole orthogonal acceleration time-of-flight (Q-TOF) mass spectrometer for studying protein phosphorylation</article-title>. <source/>Journal of the American Society for Mass Spectrometry. <year>2002</year>;<volume>13</volume>(<issue>7</issue>):<fpage>792</fpage>–<lpage>803</lpage>. <pub-id pub-id-type="doi">10.1016/S1044-0305(02)00420-8</pub-id>
<pub-id pub-id-type="pmid">12148804</pub-id></mixed-citation>
</ref>
<ref id="pone.0230977.ref029">
<label>29</label>
<mixed-citation publication-type="journal"><name><surname>Silva</surname><given-names>JC</given-names></name>, <name><surname>Denny</surname><given-names>R</given-names></name>, <name><surname>Dorschel</surname><given-names>CA</given-names></name>, <name><surname>Gorenstein</surname><given-names>M</given-names></name>, <name><surname>Kass</surname><given-names>IJ</given-names></name>, <name><surname>Li</surname><given-names>G-Z</given-names></name>, <etal>et al</etal>
<article-title>Quantitative proteomic analysis by accurate mass retention time pairs</article-title>. <source/>Analytical chemistry. <year>2005</year>;<volume>77</volume>(<issue>7</issue>):<fpage>2187</fpage>–<lpage>200</lpage>. <pub-id pub-id-type="doi">10.1021/ac048455k</pub-id>
<pub-id pub-id-type="pmid">15801753</pub-id></mixed-citation>
</ref>
<ref id="pone.0230977.ref030">
<label>30</label>
<mixed-citation publication-type="journal"><name><surname>Benjamini</surname><given-names>Y</given-names></name>, <name><surname>Hochberg</surname><given-names>Y</given-names></name>. <article-title>Controlling the false discovery rate: a practical and powerful approach to multiple testing</article-title>. <source/>Journal of the Royal statistical society: series B (Methodological). <year>1995</year>;<volume>57</volume>(<issue>1</issue>):<fpage>289</fpage>–<lpage>300</lpage>.</mixed-citation>
</ref>
<ref id="pone.0230977.ref031">
<label>31</label>
<mixed-citation publication-type="other">R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. URL <ext-link ext-link-type="uri" xlink:href="http://www.R-project.org/">http://www.R-project.org/</ext-link>(33 1) Software Vienna, Austria: R Foundation for Statistical Computing. 2013.</mixed-citation>
</ref>
<ref id="pone.0230977.ref032">
<label>32</label>
<mixed-citation publication-type="journal"><name><surname>Wickham</surname><given-names>H</given-names></name>. <article-title>ggplot2</article-title>. <source/>Wiley Interdisciplinary Reviews: Computational Statistics. <year>2011</year>;<volume>3</volume>(<issue>2</issue>):<fpage>180</fpage>–<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1002/wics.147</pub-id></mixed-citation>
</ref>
<ref id="pone.0230977.ref033">
<label>33</label>
<mixed-citation publication-type="journal"><name><surname>Schloerke</surname><given-names>B</given-names></name>, <name><surname>Crowley</surname><given-names>J</given-names></name>, <name><surname>Cook</surname><given-names>D</given-names></name>, <name><surname>Hofmann</surname><given-names>H</given-names></name>, <name><surname>Wickham</surname><given-names>H</given-names></name>, <name><surname>Briatte</surname><given-names>F</given-names></name>, <etal>et al</etal>
<source/>Ggally: Extension to ggplot2. <year>2011</year>.</mixed-citation>
</ref>
<ref id="pone.0230977.ref034">
<label>34</label>
<mixed-citation publication-type="journal"><name><surname>Salek</surname><given-names>RM</given-names></name>, <name><surname>Steinbeck</surname><given-names>C</given-names></name>, <name><surname>Viant</surname><given-names>MR</given-names></name>, <name><surname>Goodacre</surname><given-names>R</given-names></name>, <name><surname>Dunn</surname><given-names>WB</given-names></name>. <article-title>The role of reporting standards for metabolite annotation and identification in metabolomic studies</article-title>. <source/>GigaScience. <year>2013</year>;<volume>2</volume>(<issue>1</issue>):<fpage>13</fpage>-. <pub-id pub-id-type="doi">10.1186/2047-217X-2-13</pub-id> .<pub-id pub-id-type="pmid">24131531</pub-id></mixed-citation>
</ref>
<ref id="pone.0230977.ref035">
<label>35</label>
<mixed-citation publication-type="journal"><name><surname>Wishart</surname><given-names>DS</given-names></name>, <name><surname>Feunang</surname><given-names>YD</given-names></name>, <name><surname>Marcu</surname><given-names>A</given-names></name>, <name><surname>Guo</surname><given-names>AC</given-names></name>, <name><surname>Liang</surname><given-names>K</given-names></name>, <name><surname>Vázquez-Fresno</surname><given-names>R</given-names></name>, <etal>et al</etal>
<article-title>HMDB 4.0: the human metabolome database for 2018</article-title>. <source/>Nucleic acids research. <year>2018</year>;<volume>46</volume>(<issue>D1</issue>):<fpage>D608</fpage>–<lpage>D17</lpage>. Epub 2017/11/11. <pub-id pub-id-type="doi">10.1093/nar/gkx1089</pub-id> .<pub-id pub-id-type="pmid">29140435</pub-id></mixed-citation>
</ref>
<ref id="pone.0230977.ref036">
<label>36</label>
<mixed-citation publication-type="journal"><name><surname>Frolkis</surname><given-names>A</given-names></name>, <name><surname>Knox</surname><given-names>C</given-names></name>, <name><surname>Lim</surname><given-names>E</given-names></name>, <name><surname>Jewison</surname><given-names>T</given-names></name>, <name><surname>Law</surname><given-names>V</given-names></name>, <name><surname>Hau</surname><given-names>DD</given-names></name>, <etal>et al</etal>
<article-title>SMPDB: The Small Molecule Pathway Database</article-title>. <source/>Nucleic acids research. <year>2010</year>;<volume>38</volume>(<issue>Database issue</issue>):<fpage>D480</fpage>–<lpage>D7</lpage>. Epub 2009/11/30. <pub-id pub-id-type="doi">10.1093/nar/gkp1002</pub-id> .<pub-id pub-id-type="pmid">19948758</pub-id></mixed-citation>
</ref>
<ref id="pone.0230977.ref037">
<label>37</label>
<mixed-citation publication-type="other">Kyoto encyclopedia of genes and genomes, [Internet]. [cited Acessed 20 Dec 2018]. <ext-link ext-link-type="uri" xlink:href="https://www.genome.jp/kegg/">https://www.genome.jp/kegg/</ext-link></mixed-citation>
</ref>
<ref id="pone.0230977.ref038">
<label>38</label>
<mixed-citation publication-type="journal"><name><surname>Schönfeld</surname><given-names>P</given-names></name>, <name><surname>Więckowski</surname><given-names>MR</given-names></name>, <name><surname>Lebiedzińska</surname><given-names>M</given-names></name>, <name><surname>Wojtczak</surname><given-names>L</given-names></name>. <article-title>Mitochondrial fatty acid oxidation and oxidative stress: Lack of reverse electron transfer-associated production of reactive oxygen species</article-title>. <source/>Biochimica et Biophysica Acta (BBA)—Bioenergetics. <year>2010</year>;<volume>1797</volume>(<issue>6</issue>):<fpage>929</fpage>–<lpage>38</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbabio.2010.01.010</pub-id>.<pub-id pub-id-type="pmid">20085746</pub-id></mixed-citation>
</ref>
<ref id="pone.0230977.ref039">
<label>39</label>
<mixed-citation publication-type="journal"><name><surname>Baker</surname><given-names>EJ</given-names></name>, <name><surname>Miles</surname><given-names>EA</given-names></name>, <name><surname>Burdge</surname><given-names>GC</given-names></name>, <name><surname>Yaqoob</surname><given-names>P</given-names></name>, <name><surname>Calder</surname><given-names>PC</given-names></name>. <article-title>Metabolism and functional effects of plant-derived omega-3 fatty acids in humans</article-title>. <source/>Progress in Lipid Research. <year>2016</year>;<volume>64</volume>:<fpage>30</fpage>–<lpage>56</lpage>. <pub-id pub-id-type="doi">10.1016/j.plipres.2016.07.002</pub-id>. <pub-id pub-id-type="pmid">27496755</pub-id></mixed-citation>
</ref>
<ref id="pone.0230977.ref040">
<label>40</label>
<mixed-citation publication-type="journal"><name><surname>Funke</surname><given-names>C</given-names></name>, <name><surname>Schneider</surname><given-names>SA</given-names></name>, <name><surname>Berg</surname><given-names>D</given-names></name>, <name><surname>Kell</surname><given-names>DB</given-names></name>. <article-title>Genetics and iron in the systems biology of Parkinson’s disease and some related disorders</article-title>. <source/>Neurochemistry international. <year>2013</year>;<volume>62</volume>(<issue>5</issue>):<fpage>637</fpage>–<lpage>52</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuint.2012.11.015</pub-id>
<pub-id pub-id-type="pmid">23220386</pub-id></mixed-citation>
</ref>
<ref id="pone.0230977.ref041">
<label>41</label>
<mixed-citation publication-type="journal"><name><surname>Underwood</surname><given-names>BR</given-names></name>, <name><surname>Broadhurst</surname><given-names>D</given-names></name>, <name><surname>Dunn</surname><given-names>WB</given-names></name>, <name><surname>Ellis</surname><given-names>DI</given-names></name>, <name><surname>Michell</surname><given-names>AW</given-names></name>, <name><surname>Vacher</surname><given-names>C</given-names></name>, <etal>et al</etal>
<article-title>Huntington disease patients and transgenic mice have similar pro-catabolic serum metabolite profiles</article-title>. <source/>Brain. <year>2006</year>;<volume>129</volume>(<issue>4</issue>):<fpage>877</fpage>–<lpage>86</lpage>.<pub-id pub-id-type="pmid">16464959</pub-id></mixed-citation>
</ref>
<ref id="pone.0230977.ref042">
<label>42</label>
<mixed-citation publication-type="journal"><name><surname>Williamson</surname><given-names>RD</given-names></name>, <name><surname>McCarthy</surname><given-names>C</given-names></name>, <name><surname>McCarthy</surname><given-names>FP</given-names></name>, <name><surname>Kenny</surname><given-names>LC</given-names></name>. <source/>Oxidative stress in pre-eclampsia; have we been looking in the wrong place?
<year>2017</year>.</mixed-citation>
</ref>
<ref id="pone.0230977.ref043">
<label>43</label>
<mixed-citation publication-type="journal"><name><surname>Halliwell</surname><given-names>B</given-names></name>, <name><surname>Cheah</surname><given-names>IK</given-names></name>, <name><surname>Tang</surname><given-names>RMY</given-names></name>. <article-title>Ergothioneine—a diet-derived antioxidant with therapeutic potential</article-title>. <source/>FEBS Letters. <year>2018</year>;<volume>592</volume>(<issue>20</issue>):<fpage>3357</fpage>–<lpage>66</lpage>. <pub-id pub-id-type="doi">10.1002/1873-3468.13123</pub-id>
<pub-id pub-id-type="pmid">29851075</pub-id></mixed-citation>
</ref>
<ref id="pone.0230977.ref044">
<label>44</label>
<mixed-citation publication-type="journal"><name><surname>Wu</surname><given-names>G</given-names></name>, <name><surname>Fang</surname><given-names>Y-Z</given-names></name>, <name><surname>Yang</surname><given-names>S</given-names></name>, <name><surname>Lupton</surname><given-names>JR</given-names></name>, <name><surname>Turner</surname><given-names>ND</given-names></name>. <article-title>Glutathione Metabolism and Its Implications for Health</article-title>. <source/>The Journal of Nutrition. <year>2004</year>;<volume>134</volume>(<issue>3</issue>):<fpage>489</fpage>–<lpage>92</lpage>. <pub-id pub-id-type="doi">10.1093/jn/134.3.489</pub-id>
<pub-id pub-id-type="pmid">14988435</pub-id></mixed-citation>
</ref>
<ref id="pone.0230977.ref045">
<label>45</label>
<mixed-citation publication-type="journal"><name><surname>Broadhurst</surname><given-names>D</given-names></name>, <name><surname>Goodacre</surname><given-names>R</given-names></name>, <name><surname>Reinke</surname><given-names>SN</given-names></name>, <name><surname>Kuligowski</surname><given-names>J</given-names></name>, <name><surname>Wilson</surname><given-names>ID</given-names></name>, <name><surname>Lewis</surname><given-names>MR</given-names></name>, <etal>et al</etal>
<article-title>Guidelines and considerations for the use of system suitability and quality control samples in mass spectrometry assays applied in untargeted clinical metabolomic studies</article-title>. <source/>Metabolomics. <year>2018</year>;<volume>14</volume>(<issue>6</issue>):<fpage>72</fpage>
<pub-id pub-id-type="doi">10.1007/s11306-018-1367-3</pub-id>
<pub-id pub-id-type="pmid">29805336</pub-id></mixed-citation>
</ref>
<ref id="pone.0230977.ref046">
<label>46</label>
<mixed-citation publication-type="journal"><name><surname>Horgan</surname><given-names>RP</given-names></name>, <name><surname>Broadhurst</surname><given-names>DI</given-names></name>, <name><surname>Walsh</surname><given-names>SK</given-names></name>, <name><surname>Dunn</surname><given-names>WB</given-names></name>, <name><surname>Brown</surname><given-names>M</given-names></name>, <name><surname>Roberts</surname><given-names>CT</given-names></name>, <etal>et al</etal>
<article-title>Metabolic profiling uncovers a phenotypic signature of small for gestational age in early pregnancy</article-title>. <source/>Journal of proteome research. <year>2011</year>;<volume>10</volume>(<issue>8</issue>):<fpage>3660</fpage>–<lpage>73</lpage>. <pub-id pub-id-type="doi">10.1021/pr2002897</pub-id>
<pub-id pub-id-type="pmid">21671558</pub-id></mixed-citation>
</ref>
<ref id="pone.0230977.ref047">
<label>47</label>
<mixed-citation publication-type="journal"><name><surname>Forster</surname><given-names>R</given-names></name>, <name><surname>Spézia</surname><given-names>F</given-names></name>, <name><surname>Papineau</surname><given-names>D</given-names></name>, <name><surname>Sabadie</surname><given-names>C</given-names></name>, <name><surname>Erdelmeier</surname><given-names>I</given-names></name>, <name><surname>Moutet</surname><given-names>M</given-names></name>, <etal>et al</etal>
<article-title>Reproductive safety evaluation of L-Ergothioneine</article-title>. <source/>Food Chem Toxicol. <year>2015</year>;<volume>80</volume>:<fpage>85</fpage>–<lpage>91</lpage>. <pub-id pub-id-type="doi">10.1016/j.fct.2015.02.019</pub-id>. <pub-id pub-id-type="pmid">25736892</pub-id></mixed-citation>
</ref>
<ref id="pone.0230977.ref048">
<label>48</label>
<mixed-citation publication-type="journal"><name><surname>Tang</surname><given-names>RMY</given-names></name>, <name><surname>Cheah</surname><given-names>IK-M</given-names></name>, <name><surname>Yew</surname><given-names>TSK</given-names></name>, <name><surname>Halliwell</surname><given-names>B</given-names></name>. <article-title>Distribution and accumulation of dietary ergothioneine and its metabolites in mouse tissues</article-title>. <source/>Scientific reports. <year>2018</year>;<volume>8</volume>(<issue>1</issue>):<fpage>1601</fpage>
<pub-id pub-id-type="doi">10.1038/s41598-018-20021-z</pub-id>
<pub-id pub-id-type="pmid">29371632</pub-id></mixed-citation>
</ref>
<ref id="pone.0230977.ref049">
<label>49</label>
<mixed-citation publication-type="journal"><name><surname>Graham</surname><given-names>S</given-names></name>, <name><surname>Chevallier</surname><given-names>O</given-names></name>, <name><surname>Kumar</surname><given-names>P</given-names></name>, <name><surname>Türkoǧlu</surname><given-names>O</given-names></name>, <name><surname>Bahado-Singh</surname><given-names>R</given-names></name>. <article-title>Metabolomic profiling of brain from infants who died from Sudden Infant Death Syndrome reveals novel predictive biomarkers</article-title>. <source/>Journal of Perinatology. <year>2017</year>;<volume>37</volume>(<issue>1</issue>):<fpage>91</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1038/jp.2016.139</pub-id>
<pub-id pub-id-type="pmid">27608295</pub-id></mixed-citation>
</ref>
<ref id="pone.0230977.ref050">
<label>50</label>
<mixed-citation publication-type="journal"><name><surname>Vavich</surname><given-names>JM</given-names></name>, <name><surname>Howell</surname><given-names>RR</given-names></name>. <article-title>Ultraviolet-absorbing compounds in urine of normal newborns and young children</article-title>. <source/>Clinical chemistry. <year>1970</year>;<volume>16</volume>(<issue>8</issue>):<fpage>702</fpage>–<lpage>6</lpage>. <pub-id pub-id-type="pmid">5474200</pub-id></mixed-citation>
</ref>
<ref id="pone.0230977.ref051">
<label>51</label>
<mixed-citation publication-type="journal"><name><surname>Wishart</surname><given-names>DS</given-names></name>. <article-title>Emerging applications of metabolomics in drug discovery and precision medicine</article-title>. <source/>Nature reviews Drug discovery. <year>2016</year>;<volume>15</volume>(<issue>7</issue>):<fpage>473</fpage>
<pub-id pub-id-type="doi">10.1038/nrd.2016.32</pub-id>
<pub-id pub-id-type="pmid">26965202</pub-id></mixed-citation>
</ref>
<ref id="pone.0230977.ref052">
<label>52</label>
<mixed-citation publication-type="journal"><name><surname>Cai</surname><given-names>H</given-names></name>, <name><surname>Cong</surname><given-names>W-n</given-names></name>, <name><surname>Ji</surname><given-names>S</given-names></name>, <name><surname>Rothman</surname><given-names>S</given-names></name>, <name><surname>Maudsley</surname><given-names>S</given-names></name>, <name><surname>Martin</surname><given-names>B</given-names></name>. <article-title>Metabolic dysfunction in Alzheimer’s disease and related neurodegenerative disorders</article-title>. <source/>Current Alzheimer Research. <year>2012</year>;<volume>9</volume>(<issue>1</issue>):<fpage>5</fpage>–<lpage>17</lpage>. <pub-id pub-id-type="doi">10.2174/156720512799015064</pub-id>
<pub-id pub-id-type="pmid">22329649</pub-id></mixed-citation>
</ref>
<ref id="pone.0230977.ref053">
<label>53</label>
<mixed-citation publication-type="journal"><name><surname>Picca</surname><given-names>A</given-names></name>, <name><surname>Coelho-Junior</surname><given-names>HJ</given-names></name>, <name><surname>Cesari</surname><given-names>M</given-names></name>, <name><surname>Marini</surname><given-names>F</given-names></name>, <name><surname>Miccheli</surname><given-names>A</given-names></name>, <name><surname>Gervasoni</surname><given-names>J</given-names></name>, <etal>et al</etal>
<article-title>The metabolomics side of frailty: Toward personalized medicine for the aged</article-title>. <source/>Experimental gerontology. <year>2019</year>:<fpage>110692</fpage>
<pub-id pub-id-type="doi">10.1016/j.exger.2019.110692</pub-id>
<pub-id pub-id-type="pmid">31421185</pub-id></mixed-citation>
</ref>
<ref id="pone.0230977.ref054">
<label>54</label>
<mixed-citation publication-type="journal"><name><surname>Brown</surname><given-names>JM</given-names></name>, <name><surname>Hazen</surname><given-names>SL</given-names></name>. <article-title>The gut microbial endocrine organ: bacterially derived signals driving cardiometabolic diseases</article-title>. <source/>Annual review of medicine. <year>2015</year>;<volume>66</volume>:<fpage>343</fpage>–<lpage>59</lpage>. <pub-id pub-id-type="doi">10.1146/annurev-med-060513-093205</pub-id>
<pub-id pub-id-type="pmid">25587655</pub-id></mixed-citation>
</ref>
<ref id="pone.0230977.ref055">
<label>55</label>
<mixed-citation publication-type="journal"><name><surname>Shaw</surname><given-names>W</given-names></name>. <article-title>Increased urinary excretion of a 3-(3-hydroxyphenyl)-3-hydroxypropionic acid (HPHPA), an abnormal phenylalanine metabolite of Clostridia spp. in the gastrointestinal tract, in urine samples from patients with autism and schizophrenia</article-title>. <source/>Nutritional neuroscience. <year>2010</year>;<volume>13</volume>(<issue>3</issue>):<fpage>135</fpage>–<lpage>43</lpage>. <pub-id pub-id-type="doi">10.1179/147683010X12611460763968</pub-id>
<pub-id pub-id-type="pmid">20423563</pub-id></mixed-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>